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Multidrug resistance (MDR) is a major cause of chemotherapy failure. Overexpression of
ATP-binding cassette (ABC) transporters, P-glycoprotein (P-gp) and breast cancer resistance
protein (BCRP) are two well-studied drug transporters which are associated with MDR. These
two transporters also act as a major functional unit of the blood brain barrier to protect the brain
from xenobiotics and toxins. Lack of clinically approved P-gp and BCRP inhibitors renders
chemotherapy treatments of many MDR cancers ineffective and obstructs drug uptake into the
brain.

Using computational methods, we have identified new compounds that inhibit P-gp
(Brewer et al., Mol. Pharmacol. 2014). Several of these compounds show successful MDR
reversal in the drug resistant DU145TXR prostate cancer cell line (Follit et al., Pharmacol. Res.
Perspect. 2015). Here, we further analyze these P-gp inhibitors 29, 34 and 45 in a P-gp overexpressing ovarian cancer cell line, A2780ADR, and a P-gp over-expressing prostate cancer cell
line, DU145TXR. Treatment of chemotherapeutics with the in silico identified inhibitors led to a
higher mortality in MDR cancer cells in tests conducted with both conventional 2D and 3Dspheroid cell-based assays. Using a novel assay based on cellular accumulation of compounds in
a P-gp overexpressing cell line, we report that 29, 34 and 45 do not function as P-gp transport
substrates. It was found that the efficacy of chemotherapy can be enhanced by initial cotreatment
vi

of chemotherapeutics with P-gp inhibitor 29 followed by an extended treatment using only
inhibitor 29 without having chemotherapeutics in the media. Further, we describe the effects of
chemical variants of the P-gp inhibitor 29 in experiments aimed at improving the
pharmacological characteristics of the inhibitor. The variants were generated using
computational approaches or by structure-based design in attempts to improve P-gp inhibition.
Multiple variants showed an improved efficacy in reversing paclitaxel resistance in the P-gp
over-expressing DU145 TXR prostate cancer cell line. We achieved a 100% success rate using
computational lead optimization in obtaining variants of P-gp inhibitor 29 which do not function
as transport substrates of P-gp.

In related work, we developed a breast cancer cell line that overexpresses the BCRP
transporter for the purpose of identifying inhibitors of the BCRP drug pump. Three of the
variants of inhibitor 29 could reverse the BCRP-mediated MDR in this BCRP overexpressing
breast cancer cell line. Further, we identified several other compounds that interfered with BCRP
mediated transport in vitro screened from an inhouse library of small molecules.

The experimental inhibitors of P-gp and BCRP in this study appear to be promising candidates
for further development into co-therapeutics to treat MDR cancers and modulate the blood brain
barrier.
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1
1.1

CHAPTER 1: BACKGROUND

Multi Drug Resistance and ABC transporters
multidrug resistance (MDR) is termed as the ability of a disease condition to develop the

tolerance for multiple structurally or functionally different therapeutic agents simultaneously [1],
[2]. Earlier, publications on this phenomena revolved around drug resistant bacteria, but later the
development of MDR was discovered in other diseases such as cancers against chemotherapy
[3]. Although chemotherapy is the most effective method for treating metastatic cancers, MDR is
a major reason for chemotherapy failure, which can arise intrinsically or as a result of
chemotherapy itself [4], [5]. There are multiple pathways of MDR in cancers including drug
efflux, drug inactivation, alternation of drug targets, DNA damage repair and cell death
inhibition [6]. The earliest and the most studied cellular MDR mechanism is drug efflux by
transporters of the ATP-binding cassette (ABC) family [7]–[11]. Overexpression of these
transporters can lower the intracellular accumulation of various anti-cancer drugs to decrease the
efficacy of chemotherapy [12].
ABC-type transporters are found in almost all living organisms [13]. All these transporters
belong to a superfamily of proteins with seven subfamilies (designated A to G) and 48 ABC
transporters are found in humans [14]. These transporters are frequently located in cell
membranes (transmembrane) and are involved in transporting a wide variety of both organic and
inorganic substances across membranes against an electrochemical gradient utilizing the energy
from of ATP hydrolysis catalyzed by the transporters [13]–[15]. P-glycoprotein (P-gp) and
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Breast Cancer Resistance Protein (BCRP) are two important ABC-type transporters which confer
MDR in cancers by extruding anti-cancer agents out of cancer cells [16]–[18].
1.2

P-glycoprotein (P-gp)

1.2.1 P-gp structure and function
After a series of studies based on drug resistant Chinese hamster ovary cells [19]–[21],
Ling et al. in 1976 discovered a glycoprotein with a size of approximately 170 Kda and named it
the Permeability-glycoprotein as it could alter the drug permeability of cells [22]. Permeabilityglycoprotein commonly known as P-glycoprotein (P-gp) is also referred to as multidrug
resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) in the
literature [23]. Human P-gp is encoded by the MDR1 gene located at chromosome 7q21 with the
genomic sequence size of approximately 209 kb [24]. Several polymorphisms are found in
MDR1 gene which affect the pharmacokinetics of several chemotherapeutics [25].
Numerous transcriptional factors, including p53 [26] and many cell signaling pathways are
also involved in the transcriptional regulation of the P-gp gene [27]. Among those signaling
pathways, the PI3K/Akt pathway [28], the Wnt/ β-catenin pathway [29] and the MAPK/ERK
pathway [30] have been reported to positively regulate the expression of P-gp . Contradictory
studies showed that the JNK pathway is involved in both positive regulation and negative
regulation of P-gp expression [31], [32] and the p38 MAPK pathway has been shown to
negatively regulate the expression of P-gp [33]. Factors affecting the phosphorylation and
glycosylation of the protein were reported to be involved in translocation and stability, while
ubiquitination related proteins were involved in degradation of P-gp [27]. More recently
involvement of micro RNA and long non-coding RNA have been suggested to be involved in
post-transcriptional regulation of expression of P-gp [34], [35].
2

P-gp is a single polypeptide transmembrane protein with 1280 residues that contains two
homologous halves. Each half contains a transmembrane domain (TMD) with six helices
followed by a nucleotide binding domain (NBD). The two NBDs form the ATP binding sites
where energy from ATP hydrolysis is provided to extrude molecules. Several helices from both
transmembrane domains are responsible for forming the drug binding domain (DBD) which
provides the binding site(s) for various molecules [36]–[40]. In addition, a flexible linker region
between the two homologous halves of the protein plays a crucial role in bringing in two NBDs
together to form ATP-binding sites [41]. The conformational changes that occur in the NBDs as
a result of ATP binding and/or hydrolysis causes a rearrangement in transmembrane helices
which triggers the transportation of DBD bound molecules out of the cells [42]–[44]. The
glycosylation of P-gp occurs in the extracellular portion and may play a role in trafficking of Pgp into the cell surface, but this modification has not been observed to influence drug transport
[45].

3

Figure 1.1- 3-Dimensional structure of P-gp
The “open inward” crystal structure of P-gp with NBDs apart. The N-terminal half of the protein
(blue) and the C-terminal half (yellow) are connected by a flexible linker region (black dashed
line). TMD – Transmembrane domain; NBD – Nucleotide binding domain. Image is modified
from Ward et al. [46]
After the discovery of P-gp expression in cell lines with MDR phenotypes, Fojo et al. in
1987 demonstrated mRNA expression of the MDR1 gene in human tumors and healthy human
tissues such as adrenal gland, kidney, lung, liver, lower jejunum, colon, and rectum [47]. Later,
the expression of P-gp was discovered in blood capillaries involved in biological barriers such as
blood brain barrier (BBB) [48], blood testes barrier [49] and placenta [50]. This expression
pattern of P-gp in normal human tissues suggests that P-gp function may be to prevent the
accumulation of detrimental substances inside human vital organs [47], [51], [52]. The tissue
distribution patterns indicate that P-gp may play a significant role in excreting xenobiotics and
metabolites into urine and bile and into the intestinal lumen, all processes which can affect the
pharmacokinetics of drug availability in the human body [53]–[56]. Furthermore, it has been
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shown that P-gp participates in the secretion of steroid hormones such as cortisol, testosterone,
and progesterone from the adrenal gland [57].
Although humans have one MDR1 gene expressing P-gp, mice express two P-gp encoding
genes, mdr1a and mdr1b, which confer MDR [58]–[60]. It has been suggested that a double
knockout mouse of both mdr1a and mdr1b is required to study the physiological role of P-gp in
in vivo conditions to predict an equivalent impact of P-gp in humans [61]. Interestingly the
double knockout mdr1a/1b (−/−) mice did not show physiological abnormalities in viability,
development, fertility, and in a range of other biological parameters. This suggests the presence
of the other proteins or biological systems that can mimic or complement the functions of P-gp.
Most importantly, these observations suggested that transiently inhibiting P-gp in humans when
P-gp is implicated in diseases like MDR in cancer might lead to increased chemotherapeutic
efficacies [62]. Conversely, since the double knockout mdr1a/1b (−/−) mice exhibited altered
pharmacological parameters such as increased drug accumulation in the brain and modulated
activities in hematopoietic progenitor cells, therapeutic inhibition of P-gp will likely complicate
the pharmacodynamics of chemotherapies [62], [63].
1.2.2 Role of P-glycoprotein in MDR cancers
The expression and function of P-gp was first demonstrated in vitro using drug resistant
cell lines [19]–[22]. These drug resistant cell lines exhibited a simultaneous resistance to several
drugs although the cells were originally selected for the MDR phenotype with only one anticancer agent. Overexpression of P-gp in various cancer cell lines has resulted in reduced
accumulation of chemotherapeutics and exhibit resistance against various currently prescribed
anti-cancer drugs such as taxanes (paclitaxel), vinca alkaloids (vinblastine), and anthracyclines
(daunorubicin) [7].
5

Bell et al. observed the overexpression of P-gp in clinical cancer biopsy samples for the
first time in 1985. They correlated the overexpression of P-gp in advanced ovarian cancer
clinical samples with the patients’ non-responsiveness to chemotherapy using a monoclonal
antibody raised against P-gp [64]. Goldstein et al. later reported higher expression levels of P-pg
before initiation of chemotherapy in solid tumors such as colon, renal, hepatoma and pancreatic
cancers, and in both untreated or treated cancers such as neuroblastoma, acute lymphocytic
leukemia (ALL) in adults and acute nonlymphocytic leukemia (ANLL) in adults [65].
Subsequent studies have also reported similar findings of elevated P-gp expression in clinical
samples with either intrinsically or acquired resistance [66]. Poor clinical prognoses, treatment
outcomes, survival rates and drug resistances have been connected with P-gp over expression in
breast cancers [67], ovarian cancers [68], osteosarcomas [69], and acute myeloid leukemias
(AML) [70], and the results from these studies have suggested that P-gp could be therapeutically
targeted. The increased P-gp expression in human cancers after chemotherapy has been
demonstrated using the in vivo experiments. Post chemotherapy doxorubicin resistance in a
mouse model for hereditary breast cancer has been suggested to be caused by elevated levels of
both mdr1a and mdr1b genes [71]. Most importantly, this doxorubicin resistance could be
completely reversed by tariquidar, a P-pg inhibitor [71]. Unfortunately, tariquidar has shown
only marginal success in clinical trials [72]. More details about current P-gp inhibitors are
discussed in later in this chapter.
1.3

Breast cancer resistance protein (BCRP)

1.3.1 BCRP structure and function
A drug resistant breast cancer cell line that was selected with adriamycin (doxorubicin)
and verapamil which was shown not to over-express P-gp or the multidrug resistance-associated
6

protein 1 (MRP1) led to the discovery of a new type of ABC transporter named the breast cancer
resistance protein (BCRP) [73]. In concurrent work, a similar expression of BCRP was observed
in a colon carcinoma selected in the presence of mitoxantrone. In this latter work, BCRP was
reported as the “mitoxantrone resistance protein” [74]. BCRP belongs to the G subfamily of
ABC transporter superfamily, hence it is called also ABCG2 in literature [75]. Human BCRP is
encoded by the ABCG2 gene located at chromosome 4q22. Expression results in a 2.4-kb mRNA
encoding a 655- amino acid, 72 kDa polypeptide localized to the plasma membrane [76], [77]. In
contrast to P-gp expression, p53 [78], [79] and MAPK/ERK pathways were reported to be
involved in down regulation of BCRP, and upregulation of its expression was correlated with the
JNK signaling pathway [80]. In addition, microRNA-328 has exhibited down regulatory effects
in BCRP expression post-transcriptionally [81].
Unlike P-gp, BCRP is called a half transporter since the single polypeptide encoded from
ABCG2 contains only a single TMD and a NBD. Similar to several known bacterial ABC halftransporters, the BCRP l dimerizes to form a functional transporter [76]. BCRP is known to form
heterodimers between wild type monomer with a variant monomer with mutations [82]. It is
reported that cysteine (Cys603) in the extracellular loop between TMDs participates in the
stabilization of dimerization of BCRP by forming a disulfide bond [83] with its partner on the
second monomer. Each TMD region composed of six α-helices is followed by a NBD region in
the monomers. Like other ABC transporters BCRP also utilizes the energy derived from ATP
binding and hydrolysis at its NBDs after dimerization into a functional transporter to extrude
transport substrate molecules out of cells through the TMDs. Binding and hydrolysis of ATP in
the NBDs triggers a conformational change in TMDs which enables the BCRP to bind with
various structurally and functionally different molecules and release them to the outside of cells
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[84]. Several mutations in BCRP have been reported to affect the transport activity of BCRP.
Specifically, mutations in position 482, 557 and 630 can change the affinity and transporter
activity towards anti-cancer drugs such as mitoxantrone, methotrexate, doxorubicin and reporter
molecules like rhodamine 123 [85].
Beside the discovery of BCRP in drug resistant cell lines, in 1998 Allikmets et al. reported
an ABC-type transporter that was highly expressed in human placenta, which was later
discovered to be BCRP/ ABCG2 [86]. The tissue distribution of BCRP overlaps with P-gp
expression in normal, noncancerous tissues. ABCG2/BCRP is widely expressed in the placenta,
blood brain barrier, gastrointestinal tract, liver, kidney, testis, and lactating breast [87]. BCRP
also appears to play a protective role against xenobiotics and their metabolites entering vital
organs in the human body. BCRP expressed in the gut is thought to restrict the bioavailability of
orally administered drugs and to facilitate biliary and renal elimination of drugs and xenobiotics
in the liver and kidney [88].

Figure 1.2 - 3-Dimensional structure of BCRP
Cartoon representation of BCRP bound to BCRP substrate estrone-3-sulfate (E1S) in left and
BCRP bound with ATP while releasing E1S in right. Each monomer of BCRP is colored in blue
and orange. NBDs are exposed to the inside of the cell and the TMDs span through the
membrane. Image modified from Manolaridis et al. [84].
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1.3.2 Role of BCRP in MDR cancers
As noted above, BCRP was initially discovered in a breast cancer cell line selected for an
MDR phenotype by using doxorubicin and verapamil [73]. Cancer cell lines with numerous
tissue origins exposed to mitoxantrone also were observed to exhibit BCRP-mediated MDR [89].
Other than traditional cytotoxic anti-cancer drugs such as doxorubicin, daunorubicin [90],
mitoxantrone [74] and methotrexate [91], BCRP substrates include relatively novel
chemotherapeutics such as topotecan [92], SN-38 [93] and clofarabine [94]. Topotecan and SN38 are topoisomerase I inhibitors [95] and clofarabine is a nucleoside analogue [96]. Another
class of BCRP substrates are oncogenic tyrosine kinase inhibitors. Imatinib, nilotinib and
gefitinib are a few of the clinically used kinase inhibitors which are reported to interact with
BCRP, lowering the efficacy of these chemotherapeutic treatments [90]. Photosensitizers used in
photodynamic therapy are a class of molecules with the ability to generate reactive oxygen
species after absorption of light of a specific wavelength. These agents can induce apoptosis and
necrosis in treated tissues [97]. Both in vitro and in vivo experiments have indicated that BCRP
can significantly reduce the intracellular accumulation of photosensitizers and thereby reduce the
effectiveness of photodynamic therapies [98]. Surprisingly, overexpression of BCRP has also
been reported to promote a stem cell-like phenotype in prostate cells which are less responsive to
hormone based therapies [99], and a stem cell-like cell population has been reported to escape
from radiotherapy with higher mRNA expression of ABCG2 [100].
The overexpression of BCRP in cancers has mainly been reported in hematologic cancers
[77]. Numerous studies demonstrated the overexpression of BCRP in acute myelogenous
leukemia (AML) samples compared to the healthy bone marrow cells. Higher mRNA levels in
AML are correlated with relapse or refractory samples compared to the samples collected before
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the treatments [101]–[103]. Acute lymphoblastic leukemia (ALL) and chronic myelogenous
leukemia (CML) are two more hematological cancers with reported higher BCRP expression,
although more studies are required to understand the functionality of BCRP in those cancers
[104]–[106]. Other than blood related cancers, BCRP overexpression has been correlated with
poor clinical outcomes of solid tumors, breast cancers, digestive tract tumors, melanomas, and
non-small-cell lung carcinoma (NSCLC) [107]. In addition, recent studies suggest that BCRP
can be used as a marker to identify cancer stem cells (CSCs) [108]. According to a novel theory,
only CSCs in a tumor have the potential to self-renew and differentiate to maintain malignancy
and these cells facilitate tumor relapse and tumor chemotherapy resistance [109], [110].Other
studies also implicate BCRP in the chemotherapy resistance in relapsing tumors [111].
1.4

Physiological role of P-gp and BCRP in blood brain barrier
The blood brain barrier (BBB) is a structural and functional barrier between the blood and

the brain / central nervous system which acts as a gate-keeper for molecules entering the CNS.
The BBB prevents or limits the entrance of foreign materials (molecules or even cells) and
function as a protective tissue barrier for the brain. The BBB is composed of endothelial cells,
pericytes, immune cells, astrocytes, and the basement membrane. There are pores among the
endothelial cells of blood capillaries in most of the peripheral tissues allowing small molecules to
freely diffuse into the extracellular space around cells of the peripheral tissues. In contrast, the
endothelial cells in brain capillaries have adherence and tight junctions sealing the capillaries.
Further, pericytes and astrocytes also closely interact with these endothelial cells to support the
barrier function. So physically these cells prevent the entrance of relatively large molecules
allowing only the gas and small lipid soluble molecules to leave the capillaries and enter the
brain [112]–[117]. Significantly, the molecules that can diffuse through cell membranes are also
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limited in their ability to enter the CNS by the transporters that are expressed in the endothelial
membranes of the BBB [118]. ABC transporters therefore play an important active role in BBB,
and P-gp and BCRP are the two most important ABC transporters present in the BBB which
limit xenobiotic entrance to the brain [119], [120].

Figure 1.3 - Structure and the location of the blood brain barrier
Endothelial cells, astrocytes, pericytes and basal membrane together form the blood brain barrier.
P-gp, BCRP and several other transporters in endothelial cells limit the entrance of xenobiotics
from blood by extruding those back. Image modified from Helm et al. [121].
The BBB provides a massive pharmacological challenge to getting medications to reach
targets in the brain. In fact, it has been estimated that 98% of the potential drugs targeted for
central nervous system are unable to reach their target because of the BBB [122]. A considerable
number of these drugs are among those that can be extruded by the P-gp and BCRP expressed in
the BBB [123]. Imatinib and gefitinib are two tyrosine kinase inhibitors used to treat
glioblastomas and brain metastases of cancers. These compounds, as mentioned above, are also
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P-gp and BCRP substrates. The P-gp and BCRP present in the BBB thus lower the accumulation
of these inhibitors in the brain [124], [125]. Furthermore, the accumulation in the brain of
conventional chemotherapeutics like doxorubicin are also limited by P-gp and BCRP activities in
the BBB [123]. P-gp is involved in reducing brain accumulation of taxanes such as paclitaxel
[126] and BCRP can reduce the concentration of topoisomerase inhibitors such as mitoxantrone
and topotecan [123]. P-gp also limits the entrance of HIV medications [127], [128],
antihistamines [129], antidepressants [122] anti-epileptic [130] and antibiotics [131] through
BBB into the brain where desired drug targets can be located. Because of the complications that
arise from P-gp and BCRP activities in the BBB, the idea of transiently inhibiting P-pg and
BCRP by the use of co-therapeutic inhibitors has also gained considerable attention for possible
ways to successfully delivery therapeutic concentrations of drugs to the brain as much as for
MDR reversal [132].
1.5

Inhibitors of P-gp and BCRP

1.5.1 P-gp inhibitors
Tsuruo et al. in the 1980s reported the use of verapamil, a good transport substrate of P-gp,
as an MDR reversal agent in experiments performed both in vitro and in vivo [133]–[135]. Since
that time, small, drug-like molecules that can compete with or interfere with the transport activity
of P-gp (often termed modulators and inhibitors, respectively) have been extensively studied for
the purpose of reversing MDR. P-gp inhibitors are classified into three generations based on their
specificity, affinity, and toxicity[136].
The first generation inhibitors of P-gp are drugs which were used for other specific
treatments, but that have the side effect of interacting with P-gp. Like verapamil, an
antihypertensive agent, these first generation inhibitors were actually transport substrates for P12

gp and, hence, could compete with the extrusion of compounds that needed to be accumulated
inside cells [11]. This generation of inhibitors consisted of numerous pharmaceuticals which
were used for different purposes such as cardiac agents [137], antibiotics [138],
immunosuppressants [139] , and antiviral agents [140]. But these drugs also could interact with
other transporters and proteins causing unpredictable pharmacokinetics interactions.
Furthermore, some these compounds had a low affinity for P-gp and thus required high serum
concentrations to modulate P-gp activity which increases the likelihood of off-target drug
interactions [12], [141].
Second generation inhibitors were derivatives of first generation such as dexverapamil
[142] and analogues of cyclosporin A (PSC833) [139]. These compounds were modified to try to
avoid the undesirable pharmacokinetics which the first generation drugs possessed. Although
some of these compounds acted better than first generation inhibitors, they still retained
properties which limited using them as P-gp inhibitors clinically. Some of the compounds from
second generation were not specific for P-gp and increased chemotherapy related toxicities [11].
The third generation of P-gp inhibitors like tariquidar [143] were developed to overcome
the limitations of the second generation with higher specificity and affinity towards P-gp to
lower the observed toxicities. These P-gp inhibitors had been developed by using quantitative
structure-activity relationships (QSAR) and combinatorial chemistry approaches. [2]. Some of
these third generation inhibitors are still under clinical development to improve efficacy and
specificity. Inhibitors like zosuquidar and laniquidar were reported to be non substrates for P-gp
[143]. A third generation P-gp inhibitor, tariquidar has the ability to inhibit ATPase activity of Pgp thus suggested to bind with NBD or to an allosteric location [144]. However, the word
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“modulator” has been used in literature for both P-gp inhibitors such as tariquidar or P-gp pump
substrate competitive inhibitors like verapamil [145], [146].
1.5.2 BCRP inhibitors
Many studies have been performed that demonstrated the reversal of BCRP-mediated MDR
by the use of BCRP inhibitors which are non substrates for BCRP or substrates which are
competitive inhibitors of drug transport in vitro [90], [147]. Like the first generation of P-gp
modulators, BCRP substrates have been studied as competitive inhibitors of transport to reverse
the MDR phenotype. The majority of the compounds tested were tyrosine kinase inhibitors
which were also substrates of P-gp [148], [149]. Fumitremorgin C is a well-studied agent which
interfered with BCRP activity, but nevertheless showed significant neurotoxicity when the
experiments were performed in vivo [150], [151]. The fumitremorgin C analogue, Ko143, has
been reported to inhibit BCRP specifically and has exhibited promising data in vivo with less
toxicity than the parent drug [151]. The proton pump inhibitor, pantoprazole, a drug used for the
treatment of peptic ulcers, has also been used as a BCRP inhibitor in preclinical studies but
showed uncertain results [152].
1.5.3 Clinical trials of P-gp and BCRP inhibitors
P-gp inhibitors have gained only a limited success clinically, although they have been
repeatedly successful in reversing MDR in in vitro and in vivo studies [11]. A P-gp inhibitor of
first generation, verapamil, has been clinically tested in combination with adriamycin to treat
ovarian cancers and lymphomas. These clinical trials failed due to increased prevalence of side
effects such as cardiac dysfunctions including heart failures [153]–[155]. The majority of these
first generation inhibitors failed in clinical trials due to either high toxicities or lack of efficacy in
human trials [11]. In contrast, however, the use of the P-gp modulators, tetrandrine, tesmilifene
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[11] and cyclosporin A, for AML have been shown to improve clinical outcomes [156].
Specially, cyclosporin A inclusion with chemotherapy resulted in significant gains in relapse-free
and overall survival, once again raising hopes for a strategy of using P-gp inhibitors as cotherapeutics during chemotherapies [156].
Only a handful of studies among many clinical trials have reported enhanced treatment
outcomes for third generation P-gp inhibitors. The majority of the clinical trials focused on third
generation inhibitors failed to improve chemotherapy efficacy. A study focused on dofequidar
fumarate (MS-209), a P-gp and MRP-1 inhibitor, exhibited prolonged progression-free survival
of breast cancer patients without prior treatments when used in combination with the
chemotherapeutics, cyclophosphamide, doxorubicin, and fluorouracil [157]. Another study
which was focused on the use of the P-gp inhibitor, tariquidar, in combination with vinorelbine,
reduced the clearance of vinorelbine and increased its concentration in tumor masses[158].
According to a review published in 2011, there have only been five clinical trials,
concentrating solely in BCRP inhibitors and the reversal of MDR in advanced solid tumors.
These studies utilized tyrosine kinase inhibitors which are BCRP substrate as chemosensitizers in
combination with chemotherapy. Although tolerable levels of inhibitor doses were achieved,
clinical benefits were not observed [159]. Additionally, a phase III clinical trial for colorectal
cancers treated with the tyrosine kinase inhibitor, sorafenib, combined with chemotherapeutics
did not improve the outcomes for the treatment group compared to the chemotherapy only
treatment [160].
Development of compounds that inhibit both P-gp and BCRP may open BBB and increase
oral availability of therapeutics due to the overlapped expression of P-gp and BCRP at the BBB
and the epithelial of gut respectively [132], [134]. Pilot studies have reported the ability of
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enhancing blood brain permeability to drugs safely using tariquidar [161], [162]. Furthermore,
the use of elacridar, a dual inhibitor of P-gp and BCRP, was reported to significantly increased
the oral bioavailability of the chemotherapeutic, topotecan, in cancer patients [163].
Except for several inhibitors which have shown some promising data in clinical trials, the
requirement of clinically approved P-gp and BCRP inhibitors remains as a significant, unmet
medical need. Further studies are required to identify novel inhibitors of these transporters with
lower side effects for the purpose of reversing MDR in cancers, increasing BBB permeability of
drugs, as well as increasing the oral availability of important therapeutics.
1.6

Rationale
After three decades of extensive studies on reversing transporter mediated MDR in cancers,

the requirement of having a clinically approved inhibitors for P-gp and BCRP remains
unfulfilled. The demonstrated successes of P-gp inhibitors in a few clinical studies indicate the
requirement of identifying and optimizing novel inhibitors that have high specificity for the
transporters and which are intrinsically less toxic [11]. A major focus of our group is to identify
inhibitors of P-gp or BCRP which are not transport substrates for the relevant transporters. Using
high-throughput computational screenings, our group has identified many different P-gp
inhibitors (including compounds 29, 34 and 45) which reversed the paclitaxel resistance shown
in the P-gp overexpressing DU145TXR prostate cancer cell line [164], [165].
The scopes of this study are continuation of analyzing potential P-gp inhibitors 29, 34 and
45, lead optimization of 29 to improve P-gp inhibition efficacy and the identification of novel
BCRP inhibitors. Follit at el. reported the reversal of paclitaxel mediated resistance in prostate
cancer cells in vitro [165] using 29, 34 or 45. We hypothesize that these inhibitors should be
applicable with other P-gp overexpressing cancer cell lines and chemotherapeutics other than
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paclitaxel if P-gp is the accurate target of 29, 34 or 45. If these compounds are inhibiting P-gp
that will lead to a higher intracellular accumulation of P-gp substrates/ chemotherapeutics.
Higher accumulation of chemotherapeutics in cancer cells due to P-gp inhibition should then
impact the viability, apoptosis, cell migration and colony formation ability of cancer cells. Also,
our computational approach is to find P-gp inhibitors which are non P-gp substrates. Hence, we
hypothesized that intracellular accumulation of 29, 34 and 45 would not be affected by P-gp
inhibition with known P-gp inhibitors. Furthermore, if we are successful in lead optimization of
compound 29 in either conventional or computer based methods, we should be able to observe
improved efficacy in lead optimized variants of P-gp inhibitor 29 under in vitro conditions.
Finally, we expect to identify BCRP inhibitors using in vitro assays from an in house library of
small molecules which has accumulated over the time in laboratory which were initially targeted
for either BCRP, P-gp or bacterial transporter proteins.
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CHAPTER 2: TARGETED INHIBITORS OF P- GLYCOPROTEIN 29, 34 AND 45
INCREASE CHEMOTHERAPEUTIC-INDUCED MORTALITY OF MULTIDRUG
RESISTANT TUMOR CELLS

2.1

Introduction
Multidrug resistance (MDR) remains a major obstacle despite all the advances in

chemotherapy [4], [5], [65], [166]. P-gp is one of the most studied proteins regarding the reversal
of MDR in cancer [167]. The ability of P-gp to efflux a broad range of chemotherapeutics out of
the cancer cells enables the MDR in cancers [168]. Although inhibition of efflux by P-gp has
been the center of many studies of P-gp as a drug target, no clinically approved P-gp inhibitors
are available yet [11]. The majority of previous inhibitors of P-gp are indeed transport substrates
for P-gp and showed only a limited success in clinical trials, likely because of side effects
resulting from high concentrations required to inhibit P-gp [11].
Computational approaches are a rapid and economical strategy for drug discovery [169].
Research from our lab has utilized molecular dynamics and docking approaches to screen for
inhibitors of P-gp using computational homology models of P-gp [43]. A previous study by
Brewer et al. [164] employed high-throughput, parallel computational screens of a database of
drug-like structures [170], [171] to a homology model of P-gp [43]. This study [164] mainly
focused on identifying P-gp inhibitors targeting the nucleotide binding domains (NBD) of the Pgp protein without being substrates to the drug binding domains (DBD). After screening millions
of drugs like molecules from data bases, the study yielded four inhibitors that specifically
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targeted the NBDs of P-gp while avoiding interactions with the DBD. These four inhibitors
(compounds 19, 29, 34 and 45) significantly inhibited the ATPase activity of P-gp, while three of
these inhibitors (compounds 19,34 and 45) directly affected the nucleotide binding to the P-gp.
These predicted inhibitors were studied by Follit et al. [165] in the P-gp overexpressing DU145
TXR prostate cancer cell line [172]. This study revealed that 29, 34 and 45 reversed the P-gp
mediated paclitaxel resistance in DU145 TXR prostate cancer cells [165]. SMU-19 did not
reverse this drug resistance, probably due to the negative charge carried by the molecule which
likely made it cell impenetrable [165]. These inhibitors had only a modest cytotoxicity by
themselves on cancer cells as well as HFL1 non-cancerous cells [173] when these cells were
treated with inhibitor concentrations that corresponded to those used for the reversal of paclitaxel
resistance in DU145 TXR prostate cancer cells.
In the following study we further analyzed these three inhibitors. Here we show that these
three inhibitors can be used to reverse MDR in the P-gp over-expressing ovarian cancer cell line
A2780 ADR. We demonstrated the ability of these P-gp inhibitors to reverse P-gp mediated
paclitaxel and vinblastine resistance, thus reducing the viability, cell migration and colony
formation, while also increasing cell apoptosis. These inhibitors also increased the P-gp substrate
accumulation in cells as tested with daunorubicin and calcein-AM. Additionally, in this study we
introduced a novel cellular assay to identify P-gp transport substrates to confirm that the novel
inhibitors we report here are not P-gp substrates.
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2.2

Results

2.2.1 Overexpression of P-glycoprotein leads to multidrug resistance in the ovarian
cancer cell line, A2780ADR
Follit et al. [165] showed the ability of compounds 29, 34, or 45 to reverse MDR in a
prostate cancer cell line that over-expresses P-gp [172]. In the present study, we expanded our
work to a drug resistant ovarian cancer cell line. Figure 2.1A shows the characterization of
paired ovarian cancer cell lines, A2780 [174], and the highly drug resistant line derived from it,
A2780ADR [137]. Western blot analyses using a P-gp-specific primary antibody showed that
while the A2780ADR cells expressed significant amounts of P-gp (Figure 2.1A, left lane), no Pgp was detectable in the parental A2780 cells (Figure 2.1A, right lane). Also consistent with
earlier work using prostate cancer cells [137], the results using the ovarian A2780ADR cells
showed much higher resistance than the parental A2780 cell line to the vinca alkaloid,
vinblastine, when tested using a resazurin-based cell viability assay [175], [176] (Figure 2.1B).
High levels of resistance to paclitaxel by A2780ADR cells were also observed when exposing
the cells to increasing concentrations of the taxane, paclitaxel (Figure 2.1C). Inclusion of 60 µM
novobiocin, a relatively specific inhibitor of BCRP [177], or 250 µM probenecid, an inhibitor of
the multidrug resistance associated protein 1 (ABCC1, MRP-1)[178], together with vinblastine
had no effect on the sensitivity of A2780ADR cells to the chemotherapeutic (Figure 2.1B). These
results strongly suggest that the A2780ADR ovarian cancer cell line was phenotypically
multidrug resistant and that this MDR phenotype was correlated to overexpression of Pglycoprotein and not BCRP or MRP-1.
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Figure 2.1- The multidrug resistance phenotype of an ovarian cancer cell line.
A - Western blot analyses of A2780ADR (left lane) and A2780 (right lane) were performed
using anti-P-gp and anti-actin antibodies. B - Cell viability was determined using the resazurin
assay to analyze the resistance to vinblastine; diamonds, chemotherapeutic-sensitive cell line
A2780; circles, chemotherapy-resistant cell line A2780ADR; open squares, addition of 250µM
of the MRP1-specific inhibitor, probenecid; crosses, addition of 60µM of the BCRP-specific
inhibitor, novobiocin. C - Cell viability assays as in Panel B, but in the presence of paclitaxel;
diamonds, chemo-sensitive cell line A2780; circles, chemotherapy-resistance cell line
A2780ADR. Data represents the mean ± SD of 12 replicates from two independent experiments.
Some error bars are too small to be visible outside of the data points. PTX, paclitaxel; VIN,
vinblastine; NOV, novobiocin; PRO, probenecid.
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2.2.2 Inhibitors of P-glycoprotein reverse MDR phenotype of the ovarian cancer cell-line,
A2780ADR
Figure 2.2 shows the relative viability of A2780ADR cells as reported by the resazurin
assay when incubated with increasing concentrations of paclitaxel (Figure 2.2A) or vinblastine
(Figure 2.2B) with or without addition of P-gp inhibitors 29, 34, 45, or verapamil. The structures
of the compounds 29, 34 and 45 are shown in Figure 2.2C. It can be seen from Figure 2.2A and
B that the sensitivity of the MDR cell line to chemotherapeutics was increased by several orders
of magnitude in the presence of the P-gp inhibitors. Inclusion of the BCRP inhibitor, novobiocin,
or the MRP-1-inhibitor, probenecid, had no discernable effect on these cells (Table 2.1),
suggesting that neither BCRP nor MRP-1 contributed to the MDR phenotype of the cells. Table
2.1 compares the calculated IC50 values for the chemotherapeutics paclitaxel or vinblastine in
the presence or absence of P-gp inhibitors for the two ovarian cancer cell lines. No sensitization
of the non-MDR parental cell line A2780 was observed. These results suggest that the ovarian
cell line A2780ADR is multidrug resistant because of overexpression of P-gp and that its MDR
phenotype can be reversed by the inhibitors of P-gp ATPase activity, compounds 29, 34 and 45
[164], [165], as well as the P-gp transport substrate and competitive transport inhibitor,
verapamil.
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Figure 2.2 - Reversal of paclitaxel or vinblastine resistances by novel inhibitors of Pglycoprotein using metabolic viability assays.
A2780ADR cells were treated in the presence of compounds 29, 34, 45 or verapamil with the
indicated concentrations of chemotherapeutic. A - circles, paclitaxel alone; squares, paclitaxel
plus 25 µM compound 29; triangles, paclitaxel plus 25 µM compound 34; inverted triangles,
paclitaxel plus 25 µM compound 45; stars, paclitaxel plus 25 µM P-gp substrate verapamil. B circles, vinblastine alone; squares, vinblastine plus 10 µM compound 29; triangles, vinblastine
plus 10 µM compound 34; inverted triangles, vinblastine plus 10 µM compound 45; stars,
vinblastine plus 10 µM P-gp substrate verapamil. Data represents the mean ± SD of 12 replicates
from two independent experiments. C - Chemical structures of novel P-gp inhibitors 29, 34 and
45. PTX, paclitaxel; VIN, vinblastine; VER, verapamil.

23

Table 2.1 – In silico identified P-gp inhibitors reverse MDR phenotype of ovarian cancer cell
line.
IC50 concentrations of chemotherapeutics which resulted in 50% decrease in A2780ADR
viability were calculated from data as shown in Figures 1, S3 and S4 using a nonlinear, fourparameter curve fitting procedure.
paclitaxel
IC50(nmol/L)
A2780ADR

A2780

paclitaxel/vinblastine
only
+ compound 29
5 μM
10 μM
25 μM
+ compound 34
5 μM
10 μM
25 μM
+ compound 45
5 μM
10 μM
25 μM
+ verapamil
5 μM
10 μM
25 μM
+ novobiocin
60 μM
+ probenecid
250 μM
paclitaxel/vinblastine
only
+ compound 29
10 μM
+ compound 34
10 μM
+ compound 45
10 μM
+ verapamil
10 μM

Fold
sensitization

2146

vinblastine
Fold
IC50 (nmol/L) sensitization
361

121
42
7

18
52
308

52
16

7
22

57
20
4

38
107
528

42
12

9
31

122
90
10

18
24
225

49
34

7
11

53
22
8

41
99
265

19
6

19
58

475

1

525

1

5

15

5

1

14

1

5

1

14

1

4

1

16

1

5

1
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1

2.2.3 Novel P-gp inhibitors increased apoptosis in MDR prostate cancer cells when cotreated with paclitaxel
Results of resazurin viability assays with the A2780ADR cells (Figure 2.1 and Figure 2.2) show
unexpectedly high residual cell viabilities of between 25% with vinblastine and up to 60% when
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paclitaxel was used. While the overall results were consistent with increased cytotoxicity of
chemotherapeutics in the presence of P-gp inhibitors, these results did not directly demonstrate
that co-administration with inhibitor led to increased cell mortality. To test for increased cell
mortality, the adherent MDR prostate cancer cells (DU145TXR) [172] were used, since the
semi-adherent properties of A2780ADR cells made cell imaging much less reliable. In
experiments designed to assess the induction of apoptosis, DU145TXR cells were treated either
with 1 μM paclitaxel alone, 10 μM P-gp inhibitors alone, or combinations of paclitaxel with
inhibitors for 48 hours.
Analysis of these assays took advantage of the facts that acridine orange is taken up both
by viable and non-viable cells, intercalates with double stranded DNA, and emits green
fluorescence, while ethidium bromide is only taken up by non-viable cells and emits a strong red
fluorescence after interchelating with DNA [179], [180]. As shown in Figure 2.3, cells treated
with vehicle, paclitaxel or P-gp inhibitors alone showed green fluorescence with highly
organized nuclear morphologies, suggesting no induced apoptosis. In Figure 2.3B, the blue arrow
points out one such morphologically non-apoptotic nucleus. Upon combination treatment with
chemotherapeutic and P-gp inhibitors, the number of cells with shrunken, rounded, and darker
condensed cell morphologies increased (Figure 2.3A, bright field panels). The number of cells
that demonstrated obvious chromatin fragmentation also increased (Figure 2.3B, white arrows).
The number of dead cells, as indicated by ethidium bromide fluorescence also increased after cotreatments with chemotherapeutic and P-gp inhibitors (Figure 2.3B, yellow arrows) compared to
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paclitaxel only treated cells. These results indicated that paclitaxel induced apoptosis in
DU145TXR cancer cells when P-gp activity was blocked by the P-gp targeted inhibitors.

Figure 2.3 - Reversal of paclitaxel resistance by novel P-gp inhibitors induces apoptosis in
MDR prostate cancer cells.
A - DU145TXR cells were treated either with 1 μM paclitaxel alone, 10 μM of novel P-gp
inhibitors alone, or combinations of paclitaxel with P-gp inhibitors for 48 hours, followed by
staining with acridine orange and ethidium bromide. Top panels show the bright field images
while lower panels show the merged images obtained using GFP and Texas red fluorescence
filters. Both were recorded with 10X objectives. B - Enlarged images of the merged images
obtained in panel A with the treatments shown. The blue arrow represents a nucleus that is not
affected by paclitaxel. Cells in early stages of apoptosis with visible nuclear fragmentation are
indicated with white arrows, and apoptotic cells, stained red with ethidium bromide are indicated
by yellow arrows. PTX, paclitaxel; BF, bright field photomicrograph; G + R, green plus red
fluorescence composite images.
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2.2.4 Reversal of MDR by added P-gp inhibitors results in inhibition of cell proliferation
upon exposure to previously sub-lethal concentrations of chemotherapeutics
To experimentally test the hypothesis that cells which had residual metabolic activity after
co-treatment with chemotherapeutic and P-gp inhibitors were either dying or lost proliferation
ability, colony formation experiments [181] were performed. Figure 2.4A shows the results of
qualitative colony formation experiments, where A2780ADR cells were treated for 48 hours with
either vehicle alone, 0.1 µM vinblastine or 1 µM paclitaxel, 10 µM P-gp inhibitor alone, or
combinations of chemotherapeutic and P-gp inhibitor. Time of exposure to chemotherapeutic and
or inhibitor were the same as in Figure 2.2. The cells were then washed with media that did not
contain chemotherapeutic or inhibitors and were allowed to recover for 96 hours after which the
presence of cell colonies was assessed by crystal violet staining. In the presence of inhibitor in
combination with paclitaxel or vinblastine, no cell colonies were observed (Figure 2.4A). In
contrast, exposure to paclitaxel, vinblastine, or the inhibitors alone, resulted in very dense, viable
cell colonies which were qualitatively equivalent to the DMSO control (Figure 2.4A).
To more quantitatively assess cell viability and colony formation and to test a different
multidrug resistant cancer cell line, similar experiments were performed using the MDR prostate
cancer cell line, DU145TXR [172]. The conditions for these experiments were chosen to
represent the lowest exposure time and inhibitor concentration that resulted in significant
differences in the number of colonies formed. Cells were treated for 24 hours with 0.5 µM
paclitaxel alone, 5 µM inhibitor alone, or combinations of inhibitor and chemotherapeutic.
Afterwards, the media containing inhibitor and/or chemotherapeutic were removed and the cells
were allowed to recover for 120 h in the absence of chemotherapeutic or P-gp inhibitor. The cells
were fixed and stained as described above. Figure 2.4B, top panel, shows images of the crystal
27

violet stained colonies visible to the unaided eye. Figure 2.4B bottom, shows the statistical
analyses of two such independent experiments. The number of colonies formed in the presence
of paclitaxel and P-gp inhibitors was found to be significantly lower than when cells were grown
with inhibitor or chemotherapeutic alone. These results support the hypothesis that the residual
metabolic activities reported by the resazurin viability assays in Figure 2.1and Figure 2.2 were
due to the residual metabolic activities of cells that were dying, but not yet dead.
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Figure 2.4 - Reversal of chemotherapy resistances by novel inhibitors of P-glycoprotein.
A - Qualitative colony formation analyses using multidrug resistant ovarian cancer cells.
A2780ADR cells were treated with chemotherapeutics and/or inhibitors as indicated in the figure
for 48 hrs, washed and subsequently cultured for an additional 96 hours. Remaining cell colonies
were stained with crystal violet. Left column from top to bottom: vehicle (DMSO); vinblastine
(VIN) alone; compound 29 alone; vinblastine and compound 29; compound 34 alone; vinblastine
and compound 34; compound 45 alone; vinblastine and compound 45; verapamil (VER) alone;
vinblastine and verapamil. Right column from top to bottom: vehicle (DMSO); paclitaxel (PTX)
alone; compound 29 alone; paclitaxel and compound 29; compound 34 alone; paclitaxel and
compound 34; compound 45 only; paclitaxel and compound 45; verapamil (VER) alone;
paclitaxel and verapamil. The concentrations used were 0.1 µM vinblastine, 1 µM paclitaxel, 10
µM of inhibitors 29, 34, 45 or verapamil. B - Quantitative colony formation analyses using
multidrug resistant prostate cancer cells. The experiments were performed as above, except that
DU145TXR cells were seeded and grown to lower densities than in A, and exposure to
chemotherapeutic and inhibitors was for 24 hours at lower inhibitor concentrations. Top: Images
of a representative experiment showing stained colonies after 5 days of recovery. Treatments
were performed with 5 µM of P-gp inhibitors 29, 34 or 45 alone, 0.5 µM paclitaxel (PTX) alone,
or in combination. Bottom: Quantitative analysis of colonies formed in B. Each histogram
represents the average ± S.D. (n=6, three replicates from two individual experiments; **** P <
0.0001).
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2.2.5 P-glycoprotein inhibitors prevent multidrug resistant cancer cells from migrating
when exposed to chemotherapeutics that interrupt microtubule dynamics
To assess whether the P-gp inhibitors affect cancer cell migration in the presence of
chemotherapeutics, wound healing assays [182]–[184] were performed with the MDR prostate
cancer cell line [172]. Figure 2.5 shows the results of these wound healing assays under
conditions of limited cell proliferation in the absence or presence of 0.1µM vinblastine and 5µM
inhibitor 29, 34, or 45. Controls with the P-gp inhibitors alone (no chemotherapeutic present) are
also shown. Figure 2.5A shows micrographs typical of the scratch zones immediately after the
injury (zero time) and after 14 hours of incubation in low serum media. These experiments were
performed in media containing 1% serum to have a minimum effect from cell growth on wound
closure. Figure 2.5B presents the averages of the relative wound closures normalized to wound
closure in the presence of vehicle only (DMSO). Addition of vinblastine or the P-gp inhibitors by
themselves resulted in reduction of the width of the scratch wound similar to vehicle controls,
indicating that the MDR cancer cells were able to migrate into the wound site and close the
scratch gap under these non-proliferative conditions. When either of the three P-gp inhibitors
were used in combination with vinblastine, significant inhibition of wound healing was observed,
suggesting that cancer cell migration was strongly inhibited. The closing of scratch area was
limited to between 41% (vinblastine with 29 or 45) and 32% (vinblastine with 34) of those of the
vehicle only controls. There was no significant difference when 2.5 or 5 µM of inhibitor was
used in the presence of chemotherapeutic.
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Figure 2.5 - P-gp inhibitors prevent the migration of MDR cancer cells in the presence of
chemotherapeutics that target microtubule dynamics.
A - Wound healing assays. Confluent monolayers of the MDR prostate cancer cell line,
DU145TXR, were manually scratched and subsequently cultured for 14 hours under conditions
that inhibited cell proliferation. Representative 4x bright field micrographs of the scratch zones
were recorded. Closure of the scratches was then evaluated in the presence of chemotherapeutic
vinblastine (VIN) alone, P-gp inhibitors 29, 34 or 45 alone, as well as in the indicated
combinations. The edge of the wound is marked by a black line. B - Percentage wound closure.
The average percentage of wound closure under different treatment conditions was compared to
vehicle treated. Data are expressed as average ± S.D. of duplicate experiments (n = 12; **** P <
0.0001). DMSO, carrier vehicle only; VIN, 0.1 µM vinblastine; 29, 34, or 45 indicates added Pgp inhibitor at 2.5 or 5 µM.
2.2.6 The intracellular retention of transport substrates of P-glycoprotein is enhanced in
the presence of P-gp inhibitors in MDR cancer cells over-expressing P-gp
The results presented in Figure 2.2 to Figure 2.5 suggested that P-glycoprotein inhibition
leads to enhanced therapeutic efficacies. To determine whether the P-gp inhibitors caused
increased cellular retention of P-gp transport substrates, we assessed the accumulation of a
known P-gp substrate, calcein AM. Calcein AM is an uncharged, acetoxymethyl derivative of the
anionic fluorescent dye calcein and is known to be a substrate for P-gp [185]. Cellular esterases
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convert calcein AM to calcein, which is not transported by P-glycoprotein, making it a useful
fluorescent probe for P-gp transport activity.
Figure 2.6A shows that inclusion of P-gp inhibitors 29, 34, or 45 in media containing
calcein AM with the P-gp overexpressing ovarian cancer cell line, A2780ADR, resulted in
significant increases in intracellular calcein as detected by its green fluorescence. Compound 19
had been identified in earlier studies as an inhibitor of P-gp ATPase activity in cell-free
biochemical assays [164], but was shown to be ineffective in reversing multidrug resistance in
cell-based assays [165]. This is likely due a negative charge of the molecule at neutral pH,
making it unable to enter intact cells. Inclusion of the P-gp transport substrate verapamil also led
to significant increases in intracellular fluorescence, suggesting that uninhibited P-glycoprotein
activity in these cells was responsible for the low intracellular calcein accumulation observed in
the absence of added P-gp inhibitors or substrates. Addition of the BCRP-specific inhibitor,
novobiocin, or the MRP-1 specific inhibitor, probenecid, did not lead to increased intracellular
fluorescence, suggesting that BCRP and MRP-1 were not responsible for removing calcein AM
from these cells. Time courses for the changes in calcein fluorescence intensities in the presence
of the different inhibitors are shown in Figure 2.6B. The data indicate that both increased rates of
accumulation as well as increased overall intracellular concentrations of calcein were achieved
when P-gp specific inhibitors were present.
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It is worth noting that a number of cells in the uninhibited controls (Figure 2.6A and B)
also showed a few isolated puncta of fluorescence. This is hypothesized to be a consequence of
subpopulations of cells in the MDR cultures that are not over-expressing P-gp. Given the
plasticity of cancer cell genetics, this observation may be expected. Inclusion of
chemotherapeutics would be expected to decrease the number of these calcein positive cells in
the uninhibited control experiments.

Figure 2.6 - P-gp inhibitors restore calcein-AM or Daunorubicin accumulation in MDR
ovarian cancer cells.
A - Calcein-AM accumulation. Calcein AM accumulation upon P-gp inhibition was analyzed as
described in methods using A2780ADR cells. All experiments had identical components except
for the additions indicated. Additions were: DMSO, carrier vehicle at 0.5% final volume;
compounds 19, 29, 34 or 45 at 10 µM; VER, 10 μM verapamil; NOV, 60 μM novobiocin; PRO,
250 μM probenecid. Scale bars are 200 µm. B - Time course of calcein accumulation.
Fluorescence measurements were made on the entire wells during the imaging experiments
described in panel A. The increase in relative fluorescence resulting from accumulated calcein is
plotted versus the time of incubation. The indicated additions were as described in panel A. Each
data point represents the average ± S.D.
2.2.7 Cellular retention of daunorubicin in A2780ADR cells is enhanced by the addition
of P-gp inhibitors
The differential accumulation of the chemotherapeutic daunorubicin in the MDR ovarian
cancer cells in the presence and absence of various multidrug resistance pump inhibitors was
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assessed in the next set of experiments. Similar in design to the calcein AM accumulation
experiments just described, these experiments took advantage of the intrinsic red fluorescence of
daunorubicin. Figure 2.7A shows significant increases in intracellular daunorubicin fluorescence
when the cells were treated with daunorubicin in combination with 10 µM inhibitor 29, 34, or 45.
Inclusion of BCRP- or MRP-1 specific inhibitors (60 µM and 250 µM, respectively) did not
result in observable increases in intracellular daunorubicin fluorescence suggesting that these
effects were dependent on the specific inhibition of P-glycoprotein. Figure 2.7B presents the
quantification of daunorubicin accumulation as assayed in Figure 2.7A. The accumulation of
daunorubicin in the presence of the experimental P-gp inhibitors was comparable to that
observed for the non-MDR parental cell line, A2780 (Figure 2.7B).
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Figure 2.7- P-gp inhibitors restore daunorubicin accumulation in MDR ovarian cancer
cells.
A - daunorubicin accumulation. Intracellular daunorubicin accumulation in A2780ADR cells
was observed similarly to the accumulation of calcein (see panel A). After a 2 hour incubation
with 10 µM daunorubicin, fluorescence images of the cells were obtained using a Texas Red
filter. Additions were as indicated in panel A. B - Quantification of intracellular daunorubicin
accumulation. A2780ADR cells were incubated as described for panel C. After the 2 hour
incubation, cells were washed twice with cold RPMI to remove extracellular daunorubicin, and
then lysed. The fluorescence of each well was measured at excitation 488/20 nm and emission
575/20 nm. Percent accumulation of daunorubicin in A2780ADR cells was normalized to the
parental A2780 cells. Additions were as indicated in panel A. Each histogram represents the
average ± S.D. from two independent experiments (n =6; **** P < 0.0001).
2.2.8 Increased accumulation and deep penetration of calcein in 3D tumor spheroids
treated with P-gp inhibitors
To assess the ability of the targeted P-gp inhibitors to facilitate the penetration of P-gp
substrates into cells in tumor-like structures, microtumor spheroid cultures of an MDR prostate
cancer cell line [172] were produced. Incubation of the spheroids with calcein AM in the
presence of either vehicle alone or P-gp inhibitor 29, 34, or 45 showed considerably increased
calcein fluorescence (Figure 2.8A top row). The relative calcein fluorescence was visualized as
3D surface plots using the pixel intensities of the corresponding images (Figure 2.8A, lower
panel). Calcein accumulation was higher in the interior regions of the microtumors in the
presence of P-gp inhibitors than accumulation on the outside surfaces of the microtumors in the
DMSO control. These experiments suggest that calcein penetrated deeper into the interior of the
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microtumor in the presence of P-gp inhibitors. The time dependence of calcein AM uptake and
calcein accumulation in the presence or absence of compound 29 is shown in Figure 2.8B.

Figure 2.8 - P-gp inhibitors increase the accumulation and penetration of calcein-AM in
MDR prostate cancer spheroids.
A - Calcein accumulation in 3D-spheroids. Upper panel – After 100 minutes of incubation with
2.5 µM of the P-gp substrate calcein-AM, fluorescence images of the spheroids were recorded.
DMSO, 0.5% final volume; compounds 29, 34 or 45 at 15 µM. Scale bar indicates 1000 µm.
Lower panel – 3D surface plots representing the pixel intensities of the corresponding images
from the experiments above. B - Time course of calcein accumulation. Fluorescence images of
the spheroids treated with vehicle only or P-gp inhibitor 29 were obtained over 20 minute
intervals using a GFP filter as described in panel A. Increases in calcein accumulation in the
presence of compound 34 or 45 were observed to be similar to those shown with compound 29
(data not shown).
2.2.9 Increased cytotoxicity of daunorubicin in the presence of P-glycoprotein inhibitors
in multidrug resistant prostate cancer microtumors
The experiments described in Figure 2.2 to Figure 2.5 showed that the cytotoxicity of
chemotherapeutics like paclitaxel or vinblastine to MDR cancer cells in traditional 2D cell
culture was increased in the presence of the P-gp inhibitors 29, 34, or 45. It was of interest to test
whether combination treatment of P-glycoprotein inhibitors with chemotherapeutic would
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increase the cytotoxicity of chemotherapeutics in microtumors. To investigate this hypothesis,
DU145TXR spheroids were treated for 48 hours with either vehicle alone, P-gp inhibitor 29
alone, daunorubicin alone, as well as in combination with two different concentrations of
compound 29. After the treatment, reagents were removed and the spheroids were incubated with
fresh complete media for an additional 4 days. The growth of the spheroids under these
conditions is shown in Figure 2.9A. The change in size of the microtumors was quantified as the
total surface area of the spheroids. Growth of the tumors in the presence of 15 or 25 µM of 29
alone was similar to that in the presence of DMSO alone, demonstrating the low toxicity of 29.
In the presence of 1 µM daunorubicin, the tumor size did not change significantly over the
course of the experiment, while combination with 15 or 25 µM of 29 led to a ~ 60% reduction in
the size of the microtumors. Figure 2.9B shows a representative set of photomicrographs that
correspond to the end-points of these experiments. The left panel shows bright field images of
the microtumors after treatments indicated in the figure. The middle panel shows the red
fluorescence of the same microtumors upon addition of ethidium bromide, which stains dead
cells [179]. Merged images are shown in the right panel. The results indicate that the efficacy of
cancer cell killing by the daunorubicin chemotherapy treatment of these microtumors was
increased in the presence of the P-glycoprotein inhibitor 29.
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Figure 2.9 - Inhibition of P-gp leads to increased daunorubicin-induced cell death in MDR
spheroid microtumors.
A - Time course of changes in tumor area. MDR DU145TXR spheroids were prepared and
treated with P-gp inhibitory compound 29 with or without daunorubicin as described in methods.
Areas of the spheroids were calculated at each day of the experiment and fold change plotted
versus time. Values were normalized to the size of the tumor before addition of
chemotherapeutic. Each point represents average ± S.D. (n=4) B - Photomicrographs of
spheroids at the end of the experiment. At the end of the experiment, dead cells were illuminated
by ethidium bromide staining and bright field and fluorescence (Texas Red channel) micrographs
of typical spheroids were recorded. Treatments were as indicated in the panel labels. For each
spheroid shown, bright field (left), Texas Red fluorescence (middle) and merged (right) images
are shown. DNR, daunorubicin.
2.2.10 P-gp inhibitors 29, 34 and 45 do not affect P-gp protein expression levels
Previous studies have shown that reversal of multidrug resistances in cancers can
sometimes be due to lowered expression of the protein and not to direct inhibition of P-gp
transport by an experimental compound [186][187]. To test whether the inhibitors used in this
study affected P-gp expression, Western blot analyses of the P-gp overexpressing prostate cancer
cell line were performed after incubation for 48 hours with inhibitors 29, 34, or 45. The
conditions used in this experiment led to at least 17-fold sensitization of the DU145 TXR cells to

38

paclitaxel [165]. The results of the Western blot analyses are shown in Figure 2.10. No
decreases in P-gp protein expression were observed.

Figure 2.10 - P-gp expression is unchanged by compound treatment in DU145 TXR prostate cancer
cell line.

Western blots of DU145 TXR cancer cells treated with 5 μM of compounds (29, 34 or 45) and
vehicle/DMSO were performed using anti-P-gp and anti-actin antibodies. 50 µg of cell lysates
were loaded in each lane. Analyses were performed using anti-P-gp antibody C219 from Enzo
Life Sciences, NY (top) and anti-β-actin antibody from Santa Cruz Biotechnology, CA (bottom)
as described in Methods. P-gp was not detected in the parental drug sensitive DU145 prostate
cancer cell line.
2.2.11 P-gp inhibitors 29, 34 and 45 are not transport substrates of P-gp
The original premise of our search for P-gp inhibitors was that compounds that are not
transport substrates of the pump would make better lead compounds for future development for
clinical use [164], [165]. To test whether compounds 29, 34 and 45 were transport substrates,
accumulation assays were performed where DU145TXR cells were incubated with 5 µM of 29,
34 and 45 in the presence or absence of the known P-gp inhibitor tariquidar [188], [189]. A P-gp
transport substrate, daunorubicin, was used as a positive control. After incubation for 2.5 hours,
cells were washed with ice-cold buffer and counted. After cell lysis, the cell contents were
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analyzed by LC-MS/MS. The results of these analyses are shown in Figure 2.11. These studies
indicate that cellular accumulation of compounds 29, 34 and 45 was not different in the presence
or absence of tariquidar, while cellular accumulation of the P-gp substrate, daunorubicin, was
significantly increased in the presence of tariquidar. These results support the hypothesis that
compounds 29, 34 and 45 are not P-gp transport substrates.

Figure 2.11 - Compounds 29, 34 and 45 are catalytic inhibitors of P-gp and not transport substrates
Quantitative LC-MS/MS analysis of intracellular accumulation of 29 (panel A), 34 (panel B), 45
(panel C), or Daunorubicin (panel D) in DU145 TXR. Each histogram represents the average ±
S.D. (n=3, two independent experiments); ** P < 0.01; NS – not significant). DNR,
daunorubicin; TQR, tariquidar.
2.2.12 Inhibitors 34 and 45 are P-gp specific, while compound 29 also affects the breast
cancer resistance protein
In order to assess whether the inhibitors were specific for P-gp or would also inhibit other
ABC transporters, we created a BCRP-overexpressing breast cancer cell line, MCF-7 M100,
which we derived from MCF-7 cells [190] by exposing the cells to increasing, sub-lethal
concentrations of the BCRP pump substrate and chemotherapeutic, mitoxantrone [191]. Figure
2.12A shows the results of Western blot analyses of cell lysates of the MCF-7 and MCF-7 M100
cell lines indicating that the MCF-7 M100 derivative line overexpresses the BCRP protein.
Figure 2.12B shows the results of experiments that suggest that compounds 34 and 45 inhibit
only P-gp, while compound 29 inhibits both P-gp and BCRP. In these experiments, the MCF-7
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M100 cells were exposed to mitoxantrone (a BCRP substrate), verapamil (a P-gp substrate),
novobiocin or Ko143 (BCRP inhibitors), and the P-gp inhibitors 29, 34 and 45 as indicated in the
figure. Cell viability was assessed using MTT assays [192], [193]. The results indicate that
cellular viability of the MCF-7 M100 cell line was reduced when mitoxantrone was coadministered with the BCRP inhibitors, novobiocin and Ko143, but no effect was observed when
the P-pg substrate, verapamil, was added. The addition of mitoxantrone or the inhibitors
individually did not affect cell viability. Compounds 34 or 45 when co-administered with
mitoxantrone did not significantly affect the viability of MCF-7 M100 cells. Compound 29,
however, in combination with mitoxantrone, caused statistically significant reduction in cell
viability when compared to the viability of the cells in the presence of 29 alone. These results
suggest that compounds 34 and 45 are P-gp specific, while compound 29 inhibits both P-gp and
BCRP.
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Figure 2.12 - Inhibitors 34 and 45 are specific for P-gp specificity while compound 29 also
inhibits BCRP.
A - Western blot analysis of protein expression in cell lysates from breast cancer cell lines MCF7 (drug sensitive) and MCF-7 M100 (multidrug resistant). A single SDS gel was run as
described in Methods and then cut in two parts for probing with two different primary antibodies.
Top: Western blot analysis of MCF-7 and MCF-7 M100 was performed using anti BCRP
antibody B1 (from Santa Cruz Biotechnology, CA). Bottom: The lower half of the same gel was
probed with β-actin monoclonal antibody C4 (from Santa Cruz Biotechnology, CA). The
proteins loaded were of course identical in both top and bottom panels:
Lane #1 - Spectra™ Multicolor Broad Range Protein Ladder (catalog # 26623), Visible bands
from top to bottom in the two panels represent 260, 140, 100, 70, 50, 40, 35 kDa, respectively.
Lane #2 – total cell extract from cell line MCF-7 (drug sensitive breast cancer cell line), 5 µg
Lane #3 – total cell extract from cell line MCF-7 M100 (multidrug resistant breast cancer cell
line), 5 µg
B - MCF-7 M100 cells were treated with 50 nM of the chemotherapeutic mitoxantrone and either
compound 29, 34, 45 at 5 or 10 µM, verapamil at 10 µM, novobiocin at 200 µM or Ko143 at 1
µM as indicated in the figure. Each histogram presents the average ± S.D. of the determinations
(n=8, Replicates from two individual experiments; **** P < 0.0001; * P < 0.1). MNT,
mitoxantrone; VER, verapamil; NOV, novobiocin
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2.3

Methods and Materials

2.3.1 Cell lines and cell culture
The chemotherapeutic sensitive DU145 human prostate cancer cells [194] as well as the
multidrug resistant sub-line, DU145TXR [172] were generous gifts from Dr. Evan Keller
(University of Michigan, Ann Arbor, MI). The MDR DU145TXR was maintained under
positive selection pressure by supplementing complete medium with 10 nM paclitaxel (Acros
Organics, NJ). The above mentioned cell lines as well as the chemotherapeutic sensitive
A2780 ovarian cancer cells (93112519, Sigma) and the multidrug resistant A2780ADR
(93112520, Sigma) [137], [195] were maintained in complete media consisting of RPMI-1640
with L-glutamine, 10% fetal bovine serum (FBS; BioWest, Logan, UT), 100 U/mL penicillin
and 100 μg/mL streptomycin in a humidified incubator at 37 °C and 5% CO 2. The drugresistant line A2780ADR was maintained under positive selection pressure by supplementing
complete medium with 100 nM doxorubicin (Fisher Scientific, NJ). Cell culture materials
were purchased from Corning Inc. (Corning, NY) unless otherwise stated. A BCRP overexpressing breast cancer cell line (MCF-7 M100) was established by us according to a
previously described method [191]. The drug sensitive MCF-7 (ATCC) [190] breast cancer
cell line was exposed to increasing concentrations of the chemotherapeutic, mitoxantrone,
over 60 passages. The mitoxantrone resistant MCF-7 M100 cell line was maintained under
positive selection pressure by supplementing complete medium with 100 nM mitoxantrone
(Santa Cruz Biotechnology, CA).
2.3.2 Western blot analyses
Whole cell lysates were prepared using approximately five million cells from each cell
line. Cells were lysed in 500 μL of SDS buffer (125 mM Tris HCl pH 6.8, 20% v/v glycerol,
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4% w/v SDS and 2% v/v β-mercaptoethanol) containing 5 μL of protease inhibitor cocktail
(P8340, Sigma). The lysates were filtered through a spin column (QIAprep ®) by
centrifugation at 5000 rpm for 5 minutes and used for Western blot analysis. The lysate
proteins were resolved by denaturing SDS-PAGE [196] for 100 minutes at 110 V and
subsequently transferred to a PVDF membrane (Bio-Rad, CA) using a Mini Transblot cell
(Bio-Rad) for 70 minutes at 110 V. The transfer buffer contained 192 mM glycine, 25 mM
Tris, and 10% methanol. The membrane was blocked overnight at 4 °C with 4% powdered
skimmed milk in TBS-T (12 mM Tris–HCl pH 7.5, 0.5 M NaCl, 0.05% Tween 20). Washed
membranes were incubated with the P-gp mouse monoclonal antibody C219 (Enzo Life
Sciences, NY), the BCRP-specific monoclonal antibody B1 (from Santa Cruz Biotechnology,
CA), or the β-actin monoclonal antibody C4 (Santa Cruz Biotechnology, CA), diluted to
between 1:500 and 1:2000 in TBS-T and 4% powdered skimmed milk for 2 hours at room
temperature. Washed membranes were subsequently incubated for 1 hour at room temperature
with alkaline horseradish peroxidase-conjugated goat anti-mouse secondary antibody sc-2005
(Santa Cruz Biotechnology, CA) diluted to 1:10000 in TBS-T containing 4% milk powder.
Membranes were washed in TBS-T and P-gp, BCRP, or β-actin were visualized using
enhanced chemiluminescence detection (ECL kit, Thermo Scientific, IL). To evaluate P-gp
protein expression levels of cells after inhibitor treatment, DU145TXR cells were treated with
5 μM of P-gp inhibitors 29, 34 or 45 for 48 hours after which cell lysates were prepared and
Western blot analyses were performed as described above.
2.3.3 Resazurin cell viability assay
The resazurin assay is a well-established cell viability assay [197] which relies on the
reduction of the blue, water soluble resazurin to highly fluorescent resafurin [197] under the
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reducing environment in the cell. The fluorescence of resafurin is directly proportional to the
number of viable cells and can be measured by excitation at 530 nm and emission at 590 nm
[197]. The assay was performed as follows: Cells were trypsinized from monolayers and
seeded with 4000 cells in 150 μL of complete medium in a 96 well plate. After 24 hours, cells
were treated with chemotherapeutics and / or P-gp inhibitory compounds dissolved in DMSO,
or DMSO controls diluted in complete medium for 48 hours. The chemotherapeutics,
paclitaxel and vinblastine, were purchased from Acros Organics, NJ, and MP Biomedicals,
France, respectively. Upon 42 hours of treatment, resazurin assays were performed as
described in [175] using 440 μM of resazurin (Acros Organics, NJ) solution prepared in PBS
(137 mM NaCl, 2.7 mM KCl, 10 mM Na 2HPO4, 1.8 mM KH2PO4, pH 7.4). After 6 hours of
incubation with resazurin, the resulting fluorescence was measured by excitation at 530 nm
and emission at 590 nm using a Bio-Tek Synergy 2 multi-mode plate reader (Bio-Tek,
Winooski, VT). DMSO was used as the vehicle, 250 μM probenecid and 60 μM novobiocin
(both from Alfar Aesar, MA) were used as negative controls, and verapamil (MP
Biomedicals, France) was used as a positive control for P-gp inhibition. Percent viability was
calculated using DMSO treated cells as representative for 100% viability. Background
fluorescence was determined using resazurin and complete medium without cells.
% Viability =

Fluorescence of experimental cells - Background fluorescence
Fluorescence of DMSO treated cells - Background fluorescence

The results were plotted as the mean with standard deviation (SD) of twelve replicates
per concentration from at least two independent experiments. The graphical representations
and IC50 values were determined using four parameter variable slope non-linear regression,
using the following equation: Y=bottom + (top-bottom)/(1 + 10^((logIC50-X)*Hill
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Slope(GraphPad Prism™, La Jolla California, USA, Version 6.05). The reported “fold
sensitization” was calculated as follows.
Fold sensitization=

IC50 value of A2780ADR cells treated with chemotherapeutic only
IC50 value of A2780ADR or A2780 cells treated with chemotherapeutic
and P-gp inhibitory compound

2.3.4 MTT cell viability assay for BCRP over-expressing MCF-7 M100 breast cancer cell
line
MCF-7 M100 cells were trypsinized from monolayers and seeded with 2500 cells in
150 μL of complete medium in a 96 well plate. After 24 hours, cells were treated with
mitoxantrone (50 nM, Santa Cruz Biotechnology, CA) and / or P-gp inhibitory compounds
dissolved in DMSO, or DMSO controls diluted in complete medium for 96 hours. After
96 hours of treatment, MTT assays were performed as described in [198] using 5 mg/mL of
MTT (Acros Organics, NJ) solution prepared in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4, pH 7.4). After 4 hours of incubation with MTT, the media was
removed, and the formazan crystals were dissolved in 100 µL of DMSO. The absorbance at
570 nm was then measured using a BioTek Cytation 5 imaging multi-mode reader (Bio-Tek,
Winooski, VT). Data were obtained from two independent experiments. DMSO was used as
the vehicle, 200 μM of novobiocin (Alfar Aesar, MA) and 1 μM of Ko143 (Sigma) were used
as positive controls, and verapamil (MP Biomedicals, France) was used as a negative contr ol
for BCRP inhibition. Percent viability was calculated using DMSO treated cells as
representative for 100% viability.
2.3.5 Colony formation assay
Colony formation assays were performed similar to those described in [181] with slight
modifications. A2780ADR cells were seeded at 4000 cells per well in 96 well plates for
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24 hours and incubated for 48 hours with chemotherapeutics vinblastine (0.1 µM) or paclitaxel
(1 µM) alone, as well as 10 µM inhibitors, compounds 29, 34, 45 or verapamil alone, or
combinations of chemotherapeutics and inhibitors at the concentrations given above. After
48 hours, the media were replaced with drug free media and cells were allowed to grow for an
additional 96 hours. To visualize cells that had grown during that period, media were removed
from the wells of 96 well plates and cells were fixed with a mixture of methanol and acetic
acid 3:1 (v/v) solution. After 5 minutes, the fixation solution was removed and the cells were
stained with 0.5% w/v crystal violet (Alfar Aesar, MA) in 25% methanol for 30 minutes.
Finally, crystal violet was removed and the plates were washed with running water to remove
excess crystal violet. Cells that had continued to grow over the 96 hour incubation time were
visible as blue dots in nearly confluent cell colonies. No growth was observed where P -gp
inhibitors and chemotherapeutic were co-administered during the initial 48 hr incubation.
In a more quantitative colony formation assay similar to [181], DU145 TXR cells were seeded
in 24 well plates with 200 cells per well. After 24 hours, cells were treated with 500 nM
paclitaxel or 5 μM inhibitors alone, as well as combinations of inhibitors and
chemotherapeutics for 48 hours. The media was then removed and cells were allowed to form
colonies for 5 days in drug-free complete media. Cells were fixed and stained as described
above. Colonies visible to the naked eye were counted and recorded by persons blind ed to all
experimental conditions. The experiment was repeated two times.
2.3.6 Scratch assay
Scratch assays were performed as outlined previously [183] with minor modifications.
Cells were trypsinized from monolayers and diluted in complete culture medium to a density
of 25,000 cells in 300 μL cell suspension per well in 48-well plates and cultured until
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confluent. The monolayers of cells were scratched using a 200 μL pipette tip. Media was
removed and the cells were washed with PBS to remove any floating cells. Low serum (1%)
containing media was then added to the wells together with 0.1 μM vinblastine with or
without 2.5 or 5 µM P-gp inhibitory compounds, or 0.5% DMSO as a drug-carrier vehicle
control. Immediately after the scratching and media additions, the wounds were imaged using
a BioTek Cytation 5 imaging multi-mode reader (Bio-Tek, Winooski, VT). After 14 hours, the
remaining wounds were imaged again and the areas of the wounds before and after treatment
were quantified using ImageJ software [199]. The percentage of wound closures in each test
were calculated compared to vehicle treated experiments. Each individual experiment was
performed in triplicate and 2 images were obtained for each well. The whole experiment was
repeated at least once, and n = 12 was used for the statistical analysis.
2.3.7 Calcein AM assay
To assess inhibition of P-gp-catalyzed transport of the P-gp pump substrate, calcein AM,
A2780ADR cells were seeded at 40,000 cells per well in 96 wells plates and allowed to grow
in complete medium for 48 hours. Medium was removed and cells were treated with or
without 10 μM P-gp inhibitory compounds and 2.5 μM calcein AM (Life Technologies, OR)
and diluted into phenol red free RPMI 1640 media. The cells were imaged over 45 minutes in
15 minute intervals using both GFP fluorescence and bright field filters. Fluorescence wa s
measured by excitation at 485 nm with a 20 nm gate and at emission at 535 nm with a 20 nm
gate using a BioTek Cytation 5 imaging multi-mode reader (Bio-Tek, Winooski, VT). DMSO
was used as the vehicle, 10 μM experimental compound 19 (which does not penetrate intact
cells) [164], 250 μM probenecid and 60 μM novobiocin were used as negative controls, and
verapamil was used as a positive control for competitive inhibition of P-gp transport. Results
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were plotted as the mean with standard deviation (SD) of three replicates per concentration
and are representative of at least two independent experiments.
2.3.8 Daunorubicin accumulation experiments
A2780ADR cells were seeded in 96 wells plates at 150,000 cells per well in complete
media and allowed to grow overnight. Medium was then removed and cells were treated with
or without 15 μM P-gp inhibitory compounds and in the presence of 10 μM daunorubicin (MP
Biomedicals, France) diluted in complete medium. After 2.5 hours of incubation, media were
removed and cells were washed once with PBS containing DMSO 5% and once with 2%
DMSO and imaged using a Texas Red fluorescence filter and a BioTek Cytation 5 imaging
multi-mode reader.
To quantify the accumulation of daunorubicin in cells, assays were carried out as above,
but cells were lysed in 100 μL of PBS containing 0.5% SDS and 0.5% Triton X100
immediately after the washing step. The fluorescence of daunorubicin was measured using
excitation at 488 nm with a 20 nm gate and emission at 575 nm with a 20 nm gate using the
BioTek Cytation 5 imaging multi-mode reader.
2.3.9 Calcein AM uptake in spheroids
Spheroids of the multidrug resistant prostate cancer cell line, DU145TXR, were
produced as described [200] with the following modifications. Cells were trypsinized from
monolayers and diluted in complete culture medium to a density of 15000 cells in a 200 μL
cell suspension per well in 96-well plates. Prior to the experiment, all wells used for the assay
had been coated with 2.5% low melting agarose in RPMI. After seeding, the 96-well plates
were centrifuged at 600 rpm for 20 minutes. Centrifugation was repeated after 24 hours to
obtain more tightly packed spheroids. Spheroids that had formed six days after seeding were
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used for experiments. Spheroids were pretreated with 15 µM of P-gp inhibitors 29, 34 or 45
for 3 hours and then incubated with 2.5 µM of calcein-AM. Fluorescence images were
obtained every 20 minutes for a total of 100 minutes using a GFP filter. The resulting TIFF
image files were analyzed using ImageJ software and interactive 3D surface plot plugging was
used to obtain 3D graphs based on the pixel intensities of images. Each experiment was
carried out in triplicate and the whole experiment was duplicated.
2.3.10 Spheroid growth and spheroid area reduction assay
Spheroid cultures were prepared as described above except that the growth was initiated
with only 2000 cells per spheroid. Prepared plates were incubated at 37 °C for 72 hours in a
humidified incubator with 5% CO 2 for spheroid formation. The spheroids were treated with
daunorubicin at the concentrations indicated, with or without compound 29 that had been
diluted in 50 μL of complete medium. Half of the medium was replaced after every 48 hours
of incubation. The spheroids were imaged every 24 hours using a BioTek Cytation 5 imaging
multi-mode reader and the areas of the spheroids were determined using the BioTek Gen5
software. The fold change of tumor spheroid area was determined each day by comparing the
area of each spheroid to that of day one. Dead cells in the spheroid culture on day six were
visualized and imaged after staining with 10 μL of a 0.01% ethidium bromide (Fisher
Scientific, NJ) solution diluted into PBS.
2.3.11 Fluorescence microscopic analysis of cell apoptosis
Double staining with acridine orange/ ethidium bromide (AO/EB) is a reliable method to
detect apoptosis and was carried out as described in [179] with slight modifications. Briefly,
16000 cells were seeded in 48 well plates in 300 μL of complete media and incubated for
24 hours. After 24 hours, cells were treated with 1 μM paclitaxel and 10 μM P-gp inhibitory
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compounds in DMSO or DMSO controls for 48 hours. Then dual stain containing solution
AO/EB (100 μg/ml each) was added to each well and images were acquired using a BioTek
Cytation 5 imaging multi-mode reader with GFP (for green fluorescence from acridine
orange), Texas Red fluorescence (for red fluorescence from ethidium bromide) and bright
field filters.
2.3.12 Cellular Accumulation Assays for Experimental P-gp Inhibitors
DU145TXR cells were seeded in 6 well plates with ~350,000 cells per well. After
48 hours, the media was replaced with fresh media and cells were treated with 5 μM of
compounds (29, 34, or 45) and daunorubicin with or without 500 nM of tariquidar (MedKoo
Biosciences, Chapel Hill, NC, U.S.A.) Experiments were performed in triplicate. After
2.5 hours of incubation with compounds, cells were washed with Hank’s Balanced Salt
Solution (HBSS, Corning Inc. NY), harvested using trypsin, and counted. Each sample was
then washed with 2 mL of ice-cold HBSS and diluted in cold HBSS at a final concentration of
1 million cells/mL. All samples were frozen with liquid nitrogen and stored at −80 °C until
analysis. The samples were submitted to the preclinical pharmacology core laboratory in
University of Texas Southwestern for LC-MS/MS analyses. LC-MS/MS analyses were
performed in there essentially as described in [201]. 250 µl of treated or untreated cell lysate
was aliquoted into Eppendorf tubes. Blank lysates were spiked with varying concentrations of
each compound to create a standard curve. Each sample was mixed with 0.5 ml of a solution
containing 0.15% formic acid and 120 ng/ml n-benzylbenzamide internal standard in
methanol, vortexed 15 sec, incubated 10 min at RT and then centrifuged twice at 16,100 × g.
The supernatant was then analyzed by LC-MS/MS using a Sciex 4000QTRAP mass
spectrometer coupled to a Shimadzu Prominence LC. Chromatography conditions were as
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follows. Buffer A consisted of water + 0.1% formic acid and Buffer B consisted of
methanol + 0.1% formic acid for compound 29, 34, and 45 and acetonitrile + 0.1% formic acid
for daunorubicin. The column flow rate was 1.5 ml/min using an Agilent C18 XDB, 5 micro n
packing 50 × 4.6 mm column. The gradient conditions for compounds 29, 34, and 45 were 0 –
1.0 min 3% B, 1.0–2.0 min gradient to 95% B, 2.0–3.5 min 95% B, 3.5–3.6 min gradient to
3% B. 3.6–4.5 min 3% B. Gradient conditions for daunorubicin were 0–2.0 min 5% B, 2.0–
3.5 min gradient to 60% B, 3.5–5.0 min 60% B, 5.0–5.1 min gradient to 5% B, 5.1–7.5 min
5% B. Compounds were detected in MRM mode after optimization of machine parameters by
detection of the following parent/daughter ions: 459.1/278.1 for 29, 477.1/285.1 for 34,
424.1/149.0 for 45, and 528.1/321.0 for daunorubicin. N-benzyl benzamide (212.1/91.1) was
used as the internal standard. A value 3-fold above the signal obtained from blank lysate was
designated as the limit of detection (LOD). The limit of quantitation (LOQ) was defined as the
lowest concentration of standard at which back calculation yielded a concentration within
20% of theoretical and above the LOD. The LOQ for all analytes was between 0.1–0.5 ng/ml.
The protein pellet remaining after addition of organic solvent was resuspended in 25 µl of
0.1 M NaOH, boiled for 5 min, and 5 µl was mixed with 200 µl of 1:50 B:A reagent
(Thermofisher BCA Kit) in order to determine the protein concentration. A BSA standard
curve was prepared in H 2O and mixed in the same ratio. The samples were incubated 30 min
at 37 °C and read at 562 nM. Compound concentrations in the lysates were then normalized to
protein content for each sample.
2.4

Discussion
In the above study, we obtained further evidence that the P-gp inhibitors 29, 34 and 45

originally reported by Brewer et al. and Follit et al. reverse MDR by specifically inhibiting P-gp,
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in both 2-dimensional cultures of prostate and ovarian cancer cells and 3-dimensional cultures of
prostate cancer cells. We showed that the reversal of MDR is caused by specific inhibition of Pgp and that this inhibition led to increased accumulation of P-gp substrates. The decreased P-gp
transport activity was also shown not to be the result of downregulation of P-gp expression. We
showed in addition that these inhibitors are not transport substrates of P-gp. Compounds 34 and
45 were shown to be specific for P-gp, whereas compound 29 modulated the activity of the
breast cancer resistance protein and P-glycoprotein.
Worldwide in 2018, nearly 4% of cancer related deaths are due to ovarian cancer in
females and 7% of cancer related deaths are due to prostate cancer in males [202]. Chemotherapy
has been regarded as standard therapy for advanced epithelial ovarian cancer while
chemotherapy has shown to prolong life in patients with metastatic castration-resistant prostate
cancer [203], [204]. Nevertheless, MDR in chemotherapy related to P-gp is still a major
challenge to ovarian cancer treatments and castration-resistant prostate cancer [205], [206]. We
have demonstrated our findings using P-gp overexpressing ovarian cancer cell line, A2780 ADR
and the prostate cancer cell line DU145 TXR, which has been extensively used for P-gp
inhibition in earlier studies [207]–[212]. In this study we selected chemotherapeutics which are
used in clinical settings. Paclitaxel and vinblastine have been used clinically against both ovarian
and prostate cancers [213]–[216]. The P-gp substrate daunorubicin has been clinically evaluated
against acute myeloid leukemia [217]–[219] which is a cancer in blood cells known for acquiring
MDR through P-gp overexpression [220]–[222].
One of the major issues of using viability assays can be these assay values may not directly
correlated to cell proliferation or give an idea about cell death [223]–[225]. We have used wellknown resazurin (Alamar Blue) [226] or tetrazolium salts like MTT [193] assays for viability
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determination of cancer cells. Both of these assays are based on reduction ability of
metabolically active mitochondria of viable cells which can be used to calculate IC50 values.
According to Figure 2.2 approximately 50% viability was observed for the A2780ADR line at
paclitaxel concentration from 100 nM to 10 µM range treated with inhibitors. Such high viability
could be due to the residual activity of mitochondria of non-proliferating cells or cells are in
apoptosis. We wanted to evaluate whether an ovarian cancer cell underwent that kind of a
treatment can survive and start to proliferate again. According to Figure 2.4A ovarian cancer
cells treated with 1 µM of paclitaxel and 10 µM of P-gp inhibitors for 48 hours, a similar
condition to viability assay mentioned earlier failed to generate any colonies up to 96 hours after
the treatment in drug free media. This indicated that cells treated with a concentration from 100
nM to 10 µM range of paclitaxel with P-gp inhibitors may have lost proliferation capability
although metabolic activity was still relatively high as seen in the Figure 2.2 .
The inability of drugs to penetrate solid tumors is a major barrier in drug delivery [227].
We used a liquid overlay on agar method [200] to generate 3D spheroids with multidrug resistant
DU145TXR prostate cancer cells. Results of experiments using these microtumors treated with
P-gp inhibitors showed stronger accumulation of calcein AM even in internal parts of the
spheroid (Figure 2.8). In time course experiments, nearly complete tumor penetration of the
fluorescent dye was observed after about 100 minutes of incubation, suggesting that the P-gp
inhibitors affected cells inside the tumor. Increased cytotoxicity of daunorubicin in the presence
of inhibitor 29 indicated that the inclusion of the P-gp inhibitor resulted in significantly increased
cell mortality and destruction of these microtumors (Figure 2.9). Our attempts to create spheroids
from the MDR ovarian cancer cell line, A2780ADR failed due to the lack of tight association
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among cells which is required for spheroid formation. This could be as a result of low expression
of claudin 4 which is required for spheroid formation [228].
Our focus was to avoid P-gp pump substrates and identify P-gp inhibitors that were not
pump substrates like for example verapamil, which had limited or no success in clinical trials as
they were required in high systemic concentrations leading to toxicity [11]. Protein-based assays
as described in Brewer et al. [164] suggested that P-gp inhibitors 29, 34 and 45 were not P-gp
substrates. In this study we wanted to confirm that 29, 34 and 45 are not P-gp substrates in
cellular assays as well. The cellular assays based on Caco-2 cells using transwell plates that are
frequently used for recognizing P-gp substrates are laborious and expensive [229]. Here we
describe a relatively simple assay utilizing the ability of P-gp overexpressing cancer cells to
pump out P-gp substrates efficiently and accumulate those substrates upon inhibition of P-gp.
We demonstrated this using the known P-gp substrate, daunorubicin as the positive control and
tariquidar as the P-gp inhibitor. Tariquidar treatment significantly increased the daunorubicin
accumulation while such impact was not observed with compounds 29, 34 and 45 concluding
those are not P-gp substrates, suggesting that the identified inhibitors are indeed not transported
to a significant degree by P-gp.
According to Hanahan and Weinberg, the complexity of a cancer cell compared to a normal
cell can be reduced to six principles called "hallmarks" [230]. They describe that a cancer cell is
different from a normal cell, because cancer cells stimulate their own growth, are insensitive to
growth inhibitory signals, resist apoptosis, proliferate indefinitely, and sustain angiogenesis and
metastasis [230]. Chemotherapy is designed to exploit these “hallmarks”, however, overexpression of transporters of xenobiotics like P-gp allow cancer cells to survive in the presence
of chemotherapeutics [4], [231]–[234]. Combining chemotherapy with our P-gp inhibitors, we
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have shown that chemotherapy can exploit those “hallmarks” again by reducing the viability,
reducing colony formation, cell migration and increasing apoptosis in MDR cancer cells.
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3 CHAPTER 3: PROLONGED INHIBITION OF P-GLYCOPROTEIN AFTER
EXPOSURE TO CHEMOTHERAPEUTICS INCREASES CELL MORTALITY IN
MULTIDRUG RESISTANT CULTURED CANCER CELLS
3.1

Introduction

The efficacy of the various P-gp inhibitors was proven to be a success in P-gp overexpressing
cell culture models and some in vivo experiments[165], [235]–[237]. Nevertheless P-gp
inhibitors had shown only a limited success in clinical settings to date. Due to this, there are no
clinically approved P-gp inhibitors to treat P-gp overexpressing MDR cancers[11], [238]. The
minimal positive outcome of the clinical trials was mainly due to inhibitor toxicities, druginteractions, and clinical trial design problems. While, many of these initial inhibitors were P-gp
transport substrates requiring relatively high systemic concentrations for efficacy, others lacked
specificity for P-gp and led to drug interactions [11]. This highlights the requirement for novel Pgp inhibitors and novel treatment strategies to battle against P-gp overexpressing MDR cancers.
In the previous study we had shown three P-gp inhibitors (29, 34 and 45) that reversed the MDR
in ovarian and prostate cancer cell lines. The inhibition of P-gp resulted in a higher accumulation
of P-gp substrates such as the chemotherapeutic daunorubicin. These inhibitors retained 3 to 4
fold daunorubicin concentration in ovarian cells compared untreated cells [235]. In this study we
show that the accumulated chemotherapeutics can be retained in P-gp overexpressing cancer
cells by P-gp inhibitor 29 after an initial brief exposure to chemotherapeutics. This prolonged
retention of the chemotherapeutics by P-gp inhibitor 29 significantly increases the efficacy of
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treatment in prostate cell culture model. Although this study utilized in vitro methodologies, this
strategy should be further explored in in vivo and clinical settings.
3.2

Results

3.2.1 The presence of P-gp inhibitor 29 results in cellular retention of previously
accumulated daunorubicin in multidrug resistant prostate cancer cells
In experiments aimed at investigating whether the rate of release of chemotherapeutic
drugs from multidrug resistant human prostate cancer cells was affected by the continued
presence of the P-gp inhibitor, compound 29 [164], [165] (Figure 3.1D), we first exposed
DU145TXR cells [172] to daunorubicin in the presence of compound 29 to enable the cells to
significantly accumulate the chemotherapeutic. The media containing daunorubicin and
compound 29 were then removed and replaced with fresh media with or without addition of 29.
The relative rates of release of daunorubicin from the cells were observed using the intrinsic
fluorescence of the chemotherapeutic. Figure 3.1A shows a time-course of release of
daunorubicin over 105 minutes in the absence and presence of added P-gp inhibitor. The figure
clearly shows that daunorubicin release was significantly slower in the presence of 29 than it was
in its absence. Figure 3.1B shows the relative amounts of daunorubicin retained by these cells at
the end of the 105 min time-course. After washing the cells in cold PBS at the 105 minute time
point of the daunorubicin release assay, these cells were lysed as described in Methods. The total
relative fluorescence of each well was measured using the Cytation 5 to quantify the intracellular
daunorubicin accumulation. It is clear that the MDR prostate cancer cells retained significantly
more daunorubicin when incubated in the presence of inhibitor 29 than cells incubated without
P-gp inhibitor for the same period of time (Figure 3.1B, compare black bar to light gray bar).
When DU145TXR cells were incubated with daunorubicin in the presence of 29 followed by a
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release period in the absence of 29, the overall retention of daunorubicin was comparable to
experiments where cells were incubated with daunorubicin alone (Figure 3.1B, compare light
gray to dark gray bars). This indicates that the cells that were loaded with daunorubicin in the
presence of 29 released all of the daunorubicin accumulated due to P-gp inhibition within a
relatively short time period (~105 min) when P-gp inhibition was not maintained. The data also
suggest that the intracellular steady state concentration of chemotherapeutic reached in the
presence of P-gp inhibitor far exceeded the intracellular steady state concentration of therapeutic
when P-gp was not inhibited. The fluorescence micrographs presented in Figure 3.1C of cells
preloaded with daunorubicin plus 29 followed by 105 min of daunorubicin release in the
presence (right panel) or absence (left panel) of P-gp inhibitor 29 demonstrate qualitatively the
higher retention of daunorubicin observed in these MDR prostate cancer cells when P-gp
inhibition was maintained after chemotherapeutic treatment ended.
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Figure 3.1 - Effects of P-gp inhibition on the retention of daunorubicin in the multidrug
resistant prostate cancer cell line, DU145TXR.
A – Fluorescence of daunorubicin released from the cells in the presence or absence of P-gp
inhibitor 29 was measured over time and results were normalized to t = 0. In these experiments,
cells were preloaded with daunorubicin by incubation in the presence of the P-gp inhibitor 29 as
described in Methods. After the preloading, cells were washed and media were replaced with
complete media with or without 29. Results indicate that the presence of P-gp inhibitor in the
medium decreased the relative rate of daunorubicin release. Data are expressed as average ± S.D.
of duplicate experiments (n = 12; **** P < 0.0001). B – The total fluorescence of daunorubicin
accumulated in the cells was measured at the 105 min time point as indicated in A after washing
and complete lysis of the cells as described in Methods. A significant amount of daunorubicin
was retained in the cells in the presence of P-gp inhibitor 29 as opposed to those cells maintained
in its absence. The right most bar graph shows the quantity of daunorubicin accumulated in cells
that were exposed to daunorubicin for the entire time-course in the absence of P-gp inhibitor.
The figure indicates significantly decreased steady state accumulation of chemotherapeutic in the
absence P-gp inhibition compared to that observed in the continued presence of inhibitor. Data
are expressed as average ± S.D. of duplicate experiments (n = 12; **** P < 0.0001; “NS” = no
significant difference). C – Fluorescence images of daunorubicin retention in the DU145TXR
cells at the 105 min time point. After washing the cells with cold PBS as described in Methods,
fluorescence micrographs were obtained using a Cytation 5 imager and a Texas Red filter. The
concentration of compound 29 was 25 µM and daunorubicin was 10 µM. D – Structure of
compound 29.
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3.2.2 The viability of multidrug resistant, P-gp overexpressing prostate cancer cells is
reduced by extended exposure to P-gp inhibitor 29 after exposure to
chemotherapeutics
As shown in Figure 3.1, increased amounts of chemotherapeutics were retained in P-gpoverexpressing cells when the cells were continuously exposed to P-gp inhibitor 29 after removal
of chemotherapeutic from media. In order to determine if this increased retention of
chemotherapeutics in the cells in the extended presence of 29 resulted in decreased cell
viabilities, we carried out a series of resazurin viability experiments [175] as modified in [235].
In these assays, we first exposed DU145TXR cells to paclitaxel (Figure 3.2A) or vinblastine
(Figure 3.2B) in the presence of P-gp inhibitor 29 and allowed the cells to accumulate the
chemotherapeutics as described for daunorubicin in Figure 3.1. After a 2-hour pre-incubation in
the presence of inhibitor and chemotherapeutic, the media containing chemotherapeutic and
inhibitor were removed and replaced by complete media with or without P-gp inhibitor 29. This
was followed by a 22 hour incubation period, resulting in total incubation times of 24 hours.
Control groups were maintained with drug free complete media (0.5 % DMSO). It can be seen in
Figure 3.2 that treatment with the P-gp inhibitor alone for 24 hours did not significantly affect
cell viability as judged by the resazurin assay. Addition of paclitaxel (Figure 3.2A) or vinblastine
(Figure 3.2B) alone for 2 hours, or paclitaxel or vinblastine plus inhibitor 29 for two hours also
did not significantly decrease viability of these MDR prostate cancer cells when compared to the
DMSO-vehicle controls. In stark contrast, the treatment of the cells with either paclitaxel or
vinblastine in the presence of P-gp inhibitor 29 for two hours, followed by an extended P-gp
inhibitor exposure for 22 hours after washing the cells free from non-internalized
chemotherapeutic. This extended inhibitor treatment resulted in significant reduction in cell
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viability for both paclitaxel and vinblastine (gray bars in Figure 3.2A and B). The decreased
viability of the MDR cancer cells upon “extended P-gp inhibitor” treatment was not significantly
different than 24 hour continuous exposures to either paclitaxel or vinblastine alone with or
without P-gp inhibitors present (Figure 3.2A and B, rightmost three bars). These results indicate
that 2 hour exposures to chemotherapeutics combined with a 24 hour total exposure to P-gp
inhibitors decreased the viability of these MDR cancer cells equally well as compared to a
continuous 24 hour treatment with chemotherapeutic.

Figure 3.2 - The increased chemotherapeutic retention in MDR cells treated for extended
times with P-glycoprotein inhibitor 29 decreased viabilities of DU145TXR cells.
In these experiments, DU145TXR cells were preloaded with either paclitaxel (A) or vinblastine
(B) in the presence of P-gp inhibitor 29 unless indicated in the figure. After the preloading
incubation, cells were washed and media were replaced with complete media with the indicated
additions. Control experiments included exposure of the cells to DMSO alone (0.5% final
concentration), P-gp inhibitor 29 alone (25 µM), paclitaxel (PTX, 10 µM), vinblastine (VIN, 10
µM) or the combinations and times indicated. The percentage of viable cells present at the end of
the experiment is expressed as percentages of the DMSO-vehicle control experiments. Data are
expressed as averages +/- S.D. of duplicate experiments (n = 8; **** p < 0.0001). “NS” = not
significantly different. Measurements were made as described in Methods using a Cytation 5
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3.2.3 Survival of P-gp overexpressing MDR prostate cancer cells is reduced by extended
exposure to P-gp inhibitor 29 after exposure to chemotherapeutics
Figure 3.2 demonstrated that increased retention of chemotherapeutics due to extended Pgp inhibitor treatment led to decreased cellular viabilities. Although the resazurin assay is known
to respond to mitochondrial metabolism, and this in turn is correlated with cellular viability
[224], [226], it was of interest to assess whether these extended P-gp inhibitor treatments after
short chemotherapy exposures actually decreased cancer cell survival. With this aim, we
performed colony formation experiments in a manner similar to the viability experiments shown
above. In these experiments, the cells were treated with the indicated compounds
(chemotherapeutic and/ or P-gp inhibitor), were then washed and subsequently incubated for five
days in the absence of added chemotherapeutic and P-gp-inhibitor 29. At the end of the five-day
period, cells were fixed and stained, and the colonies were counted by individuals with no
knowledge of the experimental details to avoid any obvious biases. Figure 3.3A shows
representative images of crystal violet stained colonies visible to the naked eye at the end of the
experiment. Figure 3.3B shows that the observed colony numbers as shown as a percentage of
the DMSO-only control were similar to the results reported in the viability assays in Figure 3.2.
No significant difference in cell survival was observed when the cells were exposed to P-gp
inhibitor 29 for 24 hours, or 2 hour exposure to paclitaxel, or 2 hour exposure to paclitaxel and
inhibitor 29. In contrast, and similar to the viability results presented in Figure 3.2, co-treatment
of these MDR cancer cells for 2 hours with paclitaxel and P-gp inhibitor 29, followed by
extended treatment for 22 hours with only compound 29 resulted in a very significant decrease in
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cellular survival, which was only slightly surpassed by a 24 hour continuous exposure of the
cells to paclitaxel (Figure 3.3B, rightmost three bars).

Figure 3.3 - The increased chemotherapeutic retention in MDR cells treated for extended
times with P-glycoprotein inhibitor 29 decreased cell survival as assessed by colony
formation assays.
Experiments were performed similarly to those reported in Figure 3.2 except that treatments with
chemotherapeutic and / or inhibitor 29 were followed by a five day recovery period in complete
media without addition of chemotherapeutics or P-gp inhibitor. The chemotherapeutic in these
experiments was paclitaxel (PTX). At the end of the five day incubation, cells were fixed and
stained. Colony formation was assessed as described in Methods. A - Representative images of
the crystal violet stained colonies that were counted for the quantification shown in panel B. B –
Quantification of the number of colonies observed after treatments with the indicated compounds
and times. The data were normalized to the DMSO only control experiments and are expressed
as average ± S.D. of duplicate experiments (n = 6; **** P < 0.0001; * < 0.1). The concentration
of 29 and paclitaxel was 10 µM.
3.2.4 Increased retention of chemotherapeutic in MDR cancer cells treated for extended
times with P-gp inhibitor 29 reduced cell migration
Wound healing assays [182]–[184], [235] have been used to detect and quantify the ability
of cells to migrate from confluent to non-confluent growth areas. These assays use media
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containing low concentrations of serum to inhibit cellular proliferation, but these suboptimal
growth conditions do not inhibit the abilities of cells to migrate into non-confluent areas on a
culture plate. In addition, relatively short treatment times of maximally 14 hours were used to
ensure that cellular proliferation was limited. To assess whether the increased retention of
chemotherapeutics during extended treatment of MDR cancer cells with P-gp inhibitor 29 would
affect cancer cell migration, wound healing assays were performed as described in Methods
using DU145TXR. The results shown in Figure 3.4A and B suggest that 14 hour treatments with
inhibitor 29 alone or paclitaxel alone did not affect cancer cell migration relative to the vehicleonly DMSO control. A one-hour treatment of the cells with a combination of paclitaxel and P-gp
inhibitor 29 likewise did not affect cell migration. In contrast, a short 1-hour co-treatment with
chemotherapeutic and compound 29, followed by a 13-hour exposure to P-gp inhibitor 29
reduced cell migration by nearly 50 %. Similar to the results shown in Figure 3.2 and Figure 3.3,
the experiments shown in Figure 3.4 also clearly demonstrated that extended exposure to the Pgp inhibitor after relatively short exposures to chemotherapeutics dramatically enhanced the
effects of the drugs on the cancer cells. In the case of the migration assays, it should be noted
that the main mode of action of paclitaxel is blocking microtubule disassembly processes which
are required for the cytoskeletal remodeling necessary for effective cell mobility. Decreased cell
mobility is therefore consistent with continued presence of paclitaxel in the cells during
treatment with the P-gp inhibitor.

65

Figure 3.4 - Increased retention of chemotherapeutics in MDR cells treated for extended
times with P-glycoprotein inhibitor decreases cell motility as determined by wound healing
assays.
The treatments of cells with chemotherapeutic and P-gp inhibitor 29 (as indicated) were
performed similarly to those reported in Figure 3.2 and Figure 3.3 except that these assays were
designed to detect cellular migration independent of proliferation. A - Typical bright field images
at zero time and after 14 hours for the chemotherapeutic and P-gp inhibitor treatments as
indicated in the figure. Microscopy was as described in Methods using a Cytation 5 imager at 4 x
magnification. The concentration of 29 was 15 µM for the initial treatment with 0.5 µM
paclitaxel as indicated. Extended treatment of P-gp inhibitor 29 was carried out in at 7.5 µM for
13 hours. B – Results of wound healing assays are reported as a percentage of closure of the
wound after 14 hours relative to the DMSO vehicle-only controls. Cells were treated with P-gp
inhibitor 29 and paclitaxel for the times indicated. Data are expressed as average ± S.D. of
duplicate experiments (n = 12; **** P < 0.0001).

3.2.5 Cellular retention of chemotherapeutics during extended exposure to inhibitor 29
increases apoptosis in P-gp over-expressing DU145TXR cells
Although Figure 3.2 indicated that increased and prolonged retention of chemotherapeutics
in the presence of P-gp inhibitor 29 reduced metabolic activity and although the results of colony
formation assays in Figure 3.3 indicated a significant decrease in the survival of cancer cells after
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such extended inhibitor treatments, these results did not directly demonstrate increased cell
mortality via apoptotic mechanisms. To assess cell death mechanism, the cancer cells were
exposed to both acridine orange and ethidium bromide to attempt to discern early and late
morphological changes to cells undergoing apoptosis after treating the cells with
chemotherapeutic and / or inhibitor 29 for the times indicated in Figure 3.5. Acridine orange has
been shown to be taken up by both viable and non-viable cells and to intercalate into double
stranded DNA and emit green fluorescence. Ethidium bromide, also a DNA intercalating agent,
is normally taken up only by non-viable cells and emits a red fluorescence upon binding to DNA
[179], [180]. Use of these dyes allows detection of the nuclear morphology of the cells. Figure
3.5 shows that exposure of DU145TXR cells to 15 µM P-gp inhibitor 29 for 24 hours, or 10 µM
paclitaxel for 1 hour did not result in any observable signs of apoptosis, i.e. chromosomal and/or
cellular fragmentation. Under these conditions, no non-viable cells were detected by ethidium
bromide red fluorescence when compared to the DMSO-vehicle only controls (Figure 3.5, top
three panels). The blue arrows point to examples of cells possessing highly organized nuclear
morphologies typical of viable, non-apoptotic cells. Treatment of cells for 1 hour with the same
concentration of paclitaxel in the presence of P-gp inhibitor 29 also did not appreciably increase
the occurrence of cells displaying typical apoptotic morphologies (Figure 3.5, bottom left panel).
In contrast however, relatively short 1-hour exposures to paclitaxel followed by treatment with
P-gp inhibitor 29 for 23 hour dramatically increased the number of cells showing chromatin
fragmentation (white arrows, bottom center panel) and non-viable dead cells with fragmented
nuclei (yellow arrows, bottom center panel). The data strongly suggest that extended exposure of
P-gp inhibitor 29 to the cancer cells after initial paclitaxel treatment resulted in much higher
incidences of induced apoptosis. The extent of the induced apoptosis under the prolonged P-gp
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inhibitor treatments appeared to approach that resulting from a full 24 hour continuous exposure
to paclitaxel.

Figure 3.5 - Increased apoptosis in P-gp over-expressing cancer cells after chemotherapeutic
exposure when followed by extended P-gp inhibitor treatment
P-gp over-expressing prostate cancer cells, DU145TXR, were exposed to 10 µM paclitaxel with
or without 15 µM P-gp inhibitor 29 for 1 hour with or without extended P-gp inhibitor 29
treatment for another 23 hours as indicated in the figure. Cells were exposed to both acridine
orange and ethidium bromide after the treatments were concluded. Blue arrows identify cells
with highly organized nuclear morphologies typical of non-apoptotic cells. White arrows show
cells with nuclear – chromatin fragmentation typical of apoptotic cells. Yellow arrows show dead
cells with fragmented nuclei. Fluorescent images were obtained as described in Methods using a
Cytation 5 imager.
3.2.6 Cells that do not over-express P-gp are not significantly affected by extended
treatment with P-gp inhibitor 29
For further evaluation of the new inhibitor for potential future development for clinical use
it was of interest to determine whether the extended P-gp inhibitor 29 treatment after exposure to
chemotherapeutics might increase cytotoxicity of the chemotherapeutics in cells that do not overexpress P-gp. To this aim, experiments identical to those reported in Figure 3.2 were performed
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with the prostate cancer cell line, DU145 [194], that does not over-express P-glycoprotein [172]
(Figure 3.6A) and with a relatively normal human lung fibroblast cell line, HFL-1 [173] (Figure
3.6B), which also does not over-express P-gp. Cells were incubated with the either inhibitor 29
or paclitaxel alone with or without an extended P-gp inhibitor treatment in the combinations
indicated in the figure. No significant differences in cell viabilities with either the DU145 or the
HFL-1 cell lines were observed between paclitaxel plus inhibitor 29 treatments for 2 hours or the
identical treatments followed by 22 hours of exposure to P-gp inhibitor 29 (Figure 3.6A and B).
These experiments demonstrated that the extended P-gp inhibitor treatment did not increase the
toxicity of chemotherapy treatment to non-P-gp overexpressing cells.
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Figure 3.6 - Extended treatments with P-glycoprotein inhibitor do not affect cells that do not
over-express P-gp.
In these experiments, cell viability was assessed with resazurin as described for Figure 3.2. A –
DU145 cells were preloaded with paclitaxel (PTX) by incubation in the presence of 25 µM of Pgp inhibitor 29 unless otherwise indicated in the figure. After the preloading, cells were washed
and media was replaced with complete media with the indicated additions. Control experiments
included exposure of the cells to DMSO alone (0.5% final concentration), P-gp inhibitor 29
alone, paclitaxel alone, or in combinations and times indicated. Extended treatment with P-gp
inhibitor 29 was carried out for 22 hours. B – Experimental protocols as in A, but using human
lung fibroblast HFL-1 cells. For this experiment, the concentration of paclitaxel was 0.1 µM and
that of compound 29 was 25 µM as indicated. The percentage of viable cells present at the end of
the experiments were expressed as percentages of the DMSO- vehicle only control experiments.
Data are expressed as averages +/- S.D. of duplicate experiments. “NS” = not significantly
different. Measurements were made as described in Methods using a Cytation 5 imager.
3.3

Materials and methods

3.3.1 Cell lines and cell culture
The drug sensitive DU145 human prostate cancer cells [194] as well as the multidrug
resistant sub-line, DU145TXR [172] were generous gifts from Dr. Evan Keller (University of
Michigan, Ann Arbor, MI). The MDR DU145TXR cell line was maintained under positive
selection pressure by supplementing complete medium with 10 nM paclitaxel (Acros Organics,
NJ). The cell lines were maintained in complete media consisting of RPMI-1640 with L-
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glutamine, 10% fetal bovine serum (FBS; BioWest, Logan, UT or Corning, NY), 100 U/mL
penicillin and 100 μg/mL streptomycin in a humidified incubator at 37°C and 5% CO2. Cell
culture materials were purchased from Corning Inc. (Corning, NY) unless otherwise stated. The
chemotherapeutics paclitaxel and vinblastine were purchased from Acros Organics, NJ, and MP
Biomedicals, France, respectively. Human lung fibroblast cells, HFL-1 cells [173], were
maintained in complete medium consisting of F12K with L-glutamine, 10% fetal bovine serum,
100 U/mL penicillin and 100 μg/mL streptomycin in a humidified incubator at 37°C and 5%
CO2.
3.3.2 Daunorubicin accumulation and release
DU145TXR cells were seeded in 96 wells plates at 3000 cells per well in complete media
and allowed to grow until confluence. After removal of medium, the cells were treated with 25
μM P-gp inhibitory compound 29 [164] (IUPAC: 2-[(5-cyclopropyl-4H-1,2,4-triazol-3yl)sulfanyl]-N-[2-phenyl-5-(2,4,5-trimethylphenyl)-pyrazol-3-yl; SMILES:
Cc5cc(c3cc(NC(=O)CSC1N=C(N=N1)C2CC2)n(n3)c4ccccc4)c(C)cc5C, Fig. 1D) and 10 μM
daunorubicin (MP Biomedicals, France) diluted into complete medium. After 1.5 hours of
incubation, medium was removed and cells were washed three times with 200 μL of cold PBS
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4, pH 7.4). Half of the test
wells were then incubated with 25 μM P-gp inhibitor 29 diluted into phenol red free RPMI-1640
and the other half of the test wells were supplemented with phenol red free RPMI-1640
containing 0.5 % DMSO (vehicle). The fluorescence of daunorubicin released from the cells was
measured over 105 minutes in 15-minute intervals at excitation at 488/20 nm and emission at
575/20 nm using a Cytation 5 imaging multi-mode reader (BioTek, Winooski, VT).
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After 105-minutes, the amount of daunorubicin remaining in the cells was measured
qualitatively and quantitatively. To qualitatively observe the daunorubicin retained in the cells,
medium was removed and the cells were fixed with 4% para-formaldehyde in PBS. The cells
were imaged using a Cytation 5 imaging multi-mode reader with a Texas red fluorescence filter.
To quantify the daunorubicin that had remained in the cells, medium was removed from each
well and cells were lysed in 100 μL of PBS containing 0.5% SDS and 0.5% Triton X100. The
fluorescence of daunorubicin was measured using the Cytation 5 imaging multi-mode reader.
3.3.3 Resazurin cell viability assay
Cells were trypsinized from monolayers and seeded into a 96 well plate with 3000 cells in
150 μL of complete media per well. After 48 hours of incubation, cells were treated for 2 hours
with chemotherapeutics and / or P-gp inhibitor 29 dissolved in DMSO, and / or DMSO alone
diluted into complete medium. At the times indicated, cells were washed with cold PBS that did
not contain chemotherapeutic and treatment was continued for an additional 22 hours with
compound 29 alone. At 18 hours of treatment, 440 μM of resazurin (Acros Organics, NJ)
solution prepared in PBS was added for viability assays as described in [175]. The resulting
resorufin fluorescence was measured after 6 hours of incubation of the cells with resazurin by
excitation at 530 nm and emission at 590 nm using a Cytation 5. The percent viability was
calculated using the DMSO treated cells as representative for 100% viability. Background
fluorescence was determined using resazurin and complete medium without cells.
% Viability =

Fluorescence of experimental cells - Background fluorescence * 100
Fluorescence of DMSO treated cells - Background fluorescence
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The results from these assays were plotted as the mean with standard deviation (SD) of at
least eight replicates per treatment from two independent experiments using the program
GraphPad Prism™ (La Jolla California, USA, Version 7).
3.3.4 Colony formation assay
Colony formation assays were performed similar to [181] with slight modifications. DU145 TXR
cells were seeded in 24 well plates with 250 cells per well. After 24 hours, cells were treated for
2 hours with paclitaxel and / or P-gp inhibitor, compound 29, dissolved in DMSO, or DMSO
controls diluted in complete medium. The concentration of 29 and paclitaxel was 10 µM. The
cells were then washed with cold PBS and exposed to compound 29 alone (“extended 29
treatment”) for another 22 hours. The medium was then removed and cells were allowed to form
colonies for 5 days in drug- and compound 29-free complete media. To visualize the colonies,
the medium was removed and cells were fixed with a mixture of methanol and acetic acid 3:1
(v/v) solution. After 5 minutes, the fixation solution was removed and the cells were stained
with 0.5% w/v crystal violet (Alfar Aesar, MA) in 25% methanol for 30 minutes. After removal
of crystal violet, the whole plates were washed with running water to remove excess dye.
Colonies visible to the naked eye were counted and recorded by persons blinded to all
experimental conditions. The number of colonies were normalized to vehicle-treated controls as
percentages. The experiment was repeated two times with a total of three replicates each.
3.3.5 Scratch assays
Scratch assays were performed as outlined previously [183] with minor modifications.
Cells were trypsinized from monolayers and diluted in complete culture medium to a density of
45,000 cells in 400 μL cell suspension per well in 48-well plates and cultured until fully
confluent. The monolayers of cells were then scratched using a 200 μL pipette tip. The medium
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was removed and the cells were washed with PBS to remove floating cells. Immediately after the
scratching and media addition, the wounds were imaged using the Cytation 5. Complete medium
with low serum content (1% v/v) was then added to the wells together with 0.5 μM paclitaxel
with or without 15 µM P-gp inhibitor, compound 29. In the no-treatment control only 0.5% final
volume of DMSO was added in place of drugs and/or P-gp inhibitor. After 1 hour incubation,
medium was removed from all the wells and the cells were washed with cold PBS. All test wells
were incubated with 0.5% DMSO containing media with 1% FBS except for the wells that
contained compound 29 only, and the wells with extended compound 29 exposure after cotreatment with paclitaxel and compound 29. Extended treatment of P-gp inhibitor 29 was carried
out in a concentration of 7.5 µM for 13 hours. The “wounds” in the confluent cell layers were
then re-imaged and the area of the wounds before and after each treatment were quantified using
ImageJ software [199]. The percentage of wound closure in each test was calculated compared to
vehicle treated experiments. Each individual experiment was performed in triplicate and 2
images were obtained for each well. The whole experiment was repeated at least once, and n=12
was used for the statistical analysis.
3.3.6 Fluorescence microscopic analysis of cell apoptosis
Double staining with acridine orange/ ethidium bromide (AO/EB) is a reliable method to
detect apoptosis and was carried out as described in [179] with slight modifications. 16,000 cells
were seeded in 48 well plates in 300 μL of complete media and incubated for 48 hours. After 48
hours, cells were treated for 1 hour with 10 μM paclitaxel and 15 μM P-gp inhibitory compound
29 in DMSO or DMSO controls. Cells were then washed with cold PBS and an “extended
treatment” with compound 29 alone was carried out as described above for another 23 hours.
Cells not treated with compound 29 were treated with 0.5 % DMSO (vehicle). The AO/EB dual
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stain containing solution (100 μg/ml each) was then added to each well and images were
acquired using a Cytation 5 with GFP (for green fluorescence from acridine orange) and Texas
red fluorescence (for red fluorescence from ethidium bromide).
3.4

Discussion
P-gp overexpressing cancer cells can limit the drug accumulation in the cancer cells and

lower the effectiveness of the treatment [136]. Further, drug transporters such as P-gp can reduce
the bioavailability of drugs by impacting pharmacokinetics parameters such as clearance and
volume distribution [239]. Some experiments suggest that P-gp inhibitors can increase the
bioavailability of drugs [240], [241]. Therefore P-gp inhibitors can be effective against MDR
cancer, not only by increasing intracellular drug accumulation but also by increasing the
bioavailability of chemotherapeutics [242].
Approximately 10%–20% of patients with prostate cancer develop metastatic castrationresistant prostate cancer (mCRPC) which is an advanced form of prostate cancer that develops
following surgical castration [243]. Taxol based chemotherapy has been regarded as the first-line
treatment for patients with mCRPC [244]–[246]. Nevertheless MDR related to P-gp is still a
major challenge to castration-resistant prostate cancer treatments [206], [247]. In this study we
have shown that P-gp inhibitor 29 can retain the chemotherapeutic daunorubicin inside
DU145TXR [172], a P-gp overexpressing prostate cancer cell line (Figure 3.1) after a short
exposure. Continuance of the P-gp inhibitor 29 treatment without the presence of
chemotherapeutics, yielded a higher efficacy of the initial chemotherapeutic exposure (Figure 3.2
to Figure 3.5). We have demonstrated the increased efficacy of this experimental strategy of
prolonged exposure to P-gp inhibitor by observing the reduced viability, colony formation, cell
migration and increased apoptosis in MDR cancer cells. In all these assays, short term exposure
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of chemotherapeutics had no or minimal impact on cancer cells. But we have clearly
demonstrated that the retention of paclitaxel or vinblastine in cancer cells by P-gp inhibitor 29 is
responsible for the improved outcome of these assays. Further, results of viability assays and
apoptosis assays indicated that similar positive responses can be achieved by exposing the cells
to chemotherapeutics in a short time period compared to exposing for a long time period by
continuance of P-gp inhibitor 29 treatment. Clinically, the ability to reduce the exposure time of
chemotherapy might be a significant advantage when chemotherapy related toxicity is a concern
[248]–[250]. In support of this assertion is the fact that this strategy does not seem to affect the
viability in cancer cells or non-cancerous cells that do not overexpress P-gp (Figure 3.6).
Although these studies were conducted in vitro, we believe this strategy can be explored in
vivo and in clinical settings. Here we cite several clinical studies that administered P-gp
inhibitors along with chemotherapeutics [72], [251]–[254]. In all these, the doses of P-gp
inhibitors had been administered prior to or along with chemotherapeutics, without extended
treatment of the P-gp inhibitor. These studies have mentioned that the doses of P-gp inhibitors
were well tolerated by the patients but showed only a marginal increased efficacy of
chemotherapy at best. However, based on our results in cell culture model, we hypothesize that
addition of extra doses of P-gp inhibitor after the initial chemotherapy treatments would increase
the intracellular retention of chemotherapeutics. This has the potential to make a positive impact
on the outcome of chemotherapy in clinical trials influencing the bioavailability of the
chemotherapeutics.
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4

CHAPTER 4: EVALUATION OF LEAD OPTIMIZED VARIANTS OF PGLYCOPROTEIN INHIBITOR 29 IN MULTIDRUG RESISTANT CELL
CULTURE MODEL

4.1

Introduction
Computational methods have played a major role in drug design and discovery over three

decades [255]. These methods contributed to the discovery of highly effective HIV medications
(HIV protease inhibitors) like ritonavir, indinavir and saquinavir which have had a substantial
impact on reducing AIDS related deaths [256]. Currently computational drug screenings are
extensively utilized in identifying and modifying chemotherapeutics yielding experimental
anticancer drugs such as Luminespib [257]–[261]. Lead optimization has become a primary
focus in computational drug screenings [262]. High throughput computational screenings can
yield small molecules as initial hit molecules and these can be optimized into lead molecules to
increase their activity, reduce the off-target effects and improve overall pharmacology properties
[263], [264]. Conventional lead optimization involves the synthesis of analogues of lead
molecules and testing them in in vitro and in vivo assays which accounts for a considerable cost
of developing a new drug [255], [265]. Computational lead optimization can reduce this cost by
decreasing the number of molecules that have to be tested by increasing the proportion of new
leads that have desired effects [255].
We have identified and studied three P-gp inhibitors (29,34 and 45) using high throughput
computational studies and demonstrated their ability to successfully reverse MDR in P-gp
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overexpressing prostate and ovarian cancer cell lines [164], [165], [235]. Inhibitor 29 is predicted
to be an allosteric inhibitor with no effect on ATP binding on the NBD [164]. The following
study shows in vitro testing results of several variants of P-gp inhibitor 29. Three of these new
variants (216, 227 and 231) are the result from computational lead optimization using an in-lab
produced software called ChemGen (Group 1). Five of the other variants (238, 255, 278, 280 and
286) tested here were the result of conventional lead optimization (Group 2) which were

4.1 - Structures of 29 variants.
Parental P-gp inhibitor 29, Group 1/ChemGen generated 29 variants (216, 227 and 231), Group
2/Rationally synthesized 29 variants (238, 255, 278, 280 and 286)
synthesized by Dr. Lippert’s laboratory in the SMU Chemistry department.
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4.2

Results

4.2.1 ChemGen/docking (Group 1) generated variants of P-gp inhibitor 29 resensitize a
multidrug resistant, P-gp overexpressing prostate cancer cell line to paclitaxel
The mitochondrial reduction potential of cells is often used as an indicator for cell viability
using MTT assays [192], [193], [266]. Using these assays we observed that the three Group 1
derivatives of 29 predicted through ChemGen/docking routine and synthesized here, 216, 227
and 231, re-sensitized the P-gp overexpressing prostate cancer cell line, DU145TXR [172], to the
chemotherapeutic, paclitaxel. First, we analyzed the active range of the concentration of these
variants of 29. Figure 4.2 shows the viability of DU145TXR cells treated with P-gp inhibitor 29
variants 216, 227 and 231 with or without 100 nM of paclitaxel (100 nM of paclitaxel can be
tolerated by DU145TXR without any toxicity [165]). The inhibitory action of these derivatives
can be observed from 3 µM onwards. Figure 4.2 also shows that derivative 227 and 231
performed better than 29 combined with paclitaxel to lower the viability of cancer cells.
Importantly, these derivatives did not show considerable cytotoxicity by themselves (in the
absence of chemotherapeutic).
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Figure 4.2 – Reduction of viability to paclitaxel by ChemGen generated variants of the Pglycoprotein inhibitor, compound 29.
The prostate cancer cell line, DU145TXR, that over-expresses P-glycoprotein was treated with
inhibitors 216, 227 and 231 (0.5, 1, 3, 5, 7, 10 or 15 µM) with or without 100 nM of paclitaxel
(PTX). Metabolic activity assays using MTT were performed as described in Methods.
In order to calculate the IC50 values for reversing MDR in DU145TXR cells by these
inhibitors, cells were treated with fixed concentrations of inhibitors and varying doses of
paclitaxel (Figure 4.3). Analyses of the data (Table 4.1) revealed that in the presence of 3 µM
inhibitor variant 216, the observed IC50 value of paclitaxel was decreased by about 2.5 to 3-fold
when compared to the presence of the parental compound 29 and about 8-fold when compared to
paclitaxel alone. At increasing concentrations, the efficacy of variant 216 in increasing paclitaxel
toxicity decreased when compared to the parental compound 29. At the highest concentration
tested (10 µM), the 216 variant was observed to be somewhat less effective than parental
compound 29. Unlike 216, variants 227 and 231 were more effective than 29 at all
concentrations tested, resulting in 4-fold decreased paclitaxel IC50 at 3 µM when compared to
parental compound 29 and about 14-fold overall sensitization to paclitaxel when compared to
paclitaxel alone. At higher concentrations (5 to 10 µM), addition of these variants resulted in
80

increased paclitaxel toxicity by up to 500 – 1000-fold at 10 µM, as compared to ~100-fold of the
parental compound 29 at 10 µM. This data indicated that variants 227 and 231 were much better
re-sensitizers of the multidrug resistant cells to paclitaxel than the original compound 29 at all
concentrations tested, while variant 216 appeared to be marginally better than 29 at lower
concentrations. These data support the hypothesis that the ChemGen generated optimized lead
compounds and the docking analyses used to select Group 1 variants of compound 29 had
increased affinity for P-gp resulting in improved efficacy for reversing chemotherapy resistance
in a P-gp overexpressing cancer cell line than did the parental compound.

Figure 4.3 - Reversal of paclitaxel resistance by ChemGen identified variants of the Pglycoprotein inhibitor, compound 29.
The prostate cancer cell line, DU145TXR, that over-expresses P-glycoprotein was treated with
either paclitaxel (PTX) or paclitaxel and either 3, 5, 7, or 10 µM of the P-gp inhibitors (upper
left, upper right, lower left and lower right panels, respectively). Metabolic activity assays using
MTT were performed as described in Methods. Calculated IC50 values for paclitaxel in the
presence of the respective compounds calculated from this data are reported in Table 4.1.
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Table 4.1 - Increased toxicity of paclitaxel to DU145TXR in the presence of P-gp inhibitors
identified by ChemGen/docking routine.
Cytotoxicity of the chemotherapeutic, paclitaxel (PTX) to P-gp overexpressing prostate cancer
cells, DU145TXR, was determined in the absence and presence of the ChemGen designed 29variants, 216, 227 and 231. For each experimental compound IC 50 values of PTX alone or in the
presence of inhibitors, fold improvement of PTX sensitivity in the presence of inhibitor, and fold
improvement of PTX sensitivity by variants compared to parental compound 29 are given.
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4.2
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6
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7
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8.4

10 µM

4
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5

2

1060
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4.2.2 Accumulation and cellular retention of calcein AM in P-gp overexpressing prostate
cancer cells upon incubation with Group 1 SMU-29 variants
Calcein AM accumulation assays have been used by us previously to evaluate P-gpsubstrate accumulation in real time in the presence or absence of P-gp inhibitors [235]. For these
assays, P-gp overexpressing DU145TXR cells were incubated with the respective inhibitors in
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the presence of the P-gp substrate, calcein AM. Inhibition of P-gp leads to cellular accumulation
of calcein AM and to cleavage of its acetoxymethyl ester groups by cellular esterases, resulting
in the generation of the highly fluorescent compound, calcein. The anionic calcein is not a
substrate of P-gp and remains in the cells. In these assays, the relative fluorescence of cellular
calcein was measured over time and the results of these assays are shown in Figure 4.4 (left
panel). The data indicated that when these cells were treated with any of the three Group 1 29
variants, the observed cellular accumulation of fluorescent calcein was lower than upon
treatment with the parental compound 29.
To test whether the lower accumulation of calcein in the presence of the Group 1 29
variants was the result of retention of the compounds in the cellular membrane due to their
increased logP values relative to 29 (estimated logP values for 29, 216, 227 and 231 are
respectively 4.0, 6.6, 6.4 and 5.7. Values were obtained from Wise et al. unpublished), similar
calcein accumulation assays were performed after a 6-hour pre-incubation with the 29-variants
and parental compound 29, Figure 4.4 (right panel). We note for clarity that the preferential
partitioning of variants in the hydrophobic part of the cell membrane would keep them more
distant from the putative allosteric site on P-gp which is located adjacent to the membrane in the
cytoplasm. The data of Figure 4.4 suggested that calcein accumulation in the presence of the
variants was slightly improved by the 6 hrs preincubation for all Group 1 compounds compared
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to the “no preincubation” experiments, but none of the variants showed better performance in
these assays when compared to the parental compound 29.

Figure 4.4 - Cellular accumulation of the fluorescent dye, calcein, by inclusion of Group 1
variants of the P-glycoprotein inhibitor, compound 29, identified with ChemGen.
The prostate cancer cell line, DU145TXR, that over-expresses P-glycoprotein was treated with
calcein AM and without (left) or with (right) a 6-hr pre-incubation with 2 µM of the indicated Pgp inhibitors.
4.2.3 Effects of Group 2 variants on the paclitaxel sensitivity of P-glycoprotein
overexpressing prostate cancer cells, DU145TXR
MTT assays were again used to assess the efficacy of the Group 2 29-variants on sensitizing the
chemotherapy-resistant prostate cancer cell line, DU145TXR, to paclitaxel described before.
Figure 4.5 shows the viability of DU145TXR cells treated with derivatives 238, 255, 278, 280
and 286 with or without 100 nM of paclitaxel. Again, inhibitory action of these variants can be
observed at concentrations 3 µM and higher. All derivatives in Group 2 except for 286
performed better than original 29 when combined with paclitaxel to lower the viability of cancer
cells. Variant 280 (Figure 4.5) exhibited a considerable level toxicity to cancer cells by itself
even at 3 µM and 286 exhibited high toxicity at 15 µM concentration. To calculate the IC50
values for reversing MDR by these inhibitors, DU145TXR cells were treated with fixed
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concentrations of inhibitors and varying doses of paclitaxel (Figure 4.6). The data for these tests
is presented in Table 4.2 and suggest that the presence of all of the variants except for 286
increased the paclitaxel toxicities to these P-gp overexpressing cells compared to original
inhibitor 29. Compounds 238 and 255 increased paclitaxel toxicities to the greatest extents: At 5
µM concentration, compound 238 decreased the paclitaxel IC50 by about a thousand-fold, similar
to compound 255 at 7 µM. Comparison with parental compound 29 showed that 238 improved
sensitization of DU145TXR to paclitaxel by 3.4-fold at 3 µM, and by around 100-fold at 5 and 7
µM. At 10 µM, compound 238 resulted in a 300-fold decreased paclitaxel IC50 of DU145TXR
compared to parental compound 29 at the same concentration. Compound 255 also showed
substantial improvement in sensitization of DU145TXR to paclitaxel that was comparable to 238
at 3 µM, but the effect was not as pronounced at higher concentrations. The other three
compounds, 278, 280 and 286, were similar or less effective than the Group 1 variants, 216, 227
and 231. In addition, compound 280 seemed to exhibit some toxicity to the multidrug resistant
cancer cells as judged by the lowered cell viability at very low concentrations of paclitaxel in the
presence of 280 (Figure 4.6).
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Figure 4.5 - Reduction of viability to paclitaxel by Group 2 variants of the P-glycoprotein
inhibitor, compound 29.
The prostate cancer cell line, DU145TXR, that over-expresses P-glycoprotein was treated with
inhibitors 238, 255, 278, 280 and 286 (0.5, 1, 3, 5, 7, 10 or 15 µM) with or without 100 nM of
paclitaxel (PTX). Metabolic activity assays using MTT were performed as described in Methods.

86

Figure 4.6 - Reversal of paclitaxel resistance by rationally designed variants of the Pglycoprotein inhibitor, compound 29.
The prostate cancer cell line, DU145TXR, that over-expresses P-glycoprotein was treated with
either paclitaxel (PTX) or paclitaxel and either 3, 5, 7, or 10 µM of the P-gp inhibitors (upper
left, upper right, lower left and lower right panels, respectively). Metabolic activity assays using
MTT were performed as described in Methods. Calculated IC50 values for paclitaxel in the
presence of the respective compounds calculated from this data are reported in Table 4.2.
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Table 4.2 - Increased toxicity of paclitaxel in the presence of rationally designed P-gp
inhibitors.
Cytotoxicity of the chemotherapeutic, paclitaxel (PTX) in P-gp overexpressing prostate cancer
cells, DU145TXR, was determined in the absence and presence of the structural 29-variants,
238, 255, 276, 280, and 286. For each experimental compound, (a) IC 50 values of PTX alone or
in the presence of inhibitors (in nM), (b) Fold improvement of PTX sensitivity in the presence of
inhibitor, and (c) Fold improvement of PTX sensitivity by variants compared to parental
compound 29 are given.
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4.2.4 Accumulation and cellular retention of calcein AM in DU145TXR in the presence of
29-variants from Group 2
Figure 4.7, left, shows that without pre-incubation, the presence of 5 µM of compounds
238 and 255 resulted in considerably increased calcein accumulation in DU145TXR cells when
compared to 29. The effect of compound 286 was comparable to 29, while 278 and 280 caused
less calcein accumulation than the parental compound. After a 6-hour pre-incubation (Figure 4.7
– right panel), the effectiveness of inhibiting P-gp catalyzed transport of calcein AM remained
strongest for the more polar 29 variants 238 and 255, while that of the more hydrophobic
variants 278, 280 and 286 was comparable to 29.

Figure 4.7 - Cellular accumulation of the fluorescent dye, calcein, by inclusion of Group 2
variants of the P-glycoprotein inhibitor, compound 29.
The prostate cancer cell line, DU145TXR, that over-expresses P-glycoprotein was treated with
calcein AM and without (left) or with (right) a 6-hr pre-incubation with 2 µM of the indicated Pgp inhibitors.
4.2.5 Intracellular accumulation of compound 29 variants
Cell accumulation assays for each of the 29 variants were performed as in [235] to more
directly assess whether the compounds were indeed transport substrates or not for P-gp. These
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assays measured the intracellular accumulation of the experimental compounds using LCMS/MS methods after incubation with the P-gp over-expressing cell line, DU145TXR, in the
absence and presence of the strong P-gp inhibitor, tariquidar [267] (TQR). The concertation of
29 variants accumulated intracellularly normalized to cell lysate protein concertation is reported
in Table 4.3. Low levels of cellular accumulation of a compound in the absence of tariquidar
accompanied by much higher levels of accumulation in the presence of tariquidar suggests that
the compound in question may be a transport substrate of P-gp. In other words, if a compound is
an effective transport substrate for P-gp, active P-glycoprotein in these cells would limit
intracellular accumulation, while inhibited P-gp would result in higher intracellular
concentrations. Daunorubicin (DNR) is an example of a good transport substrate for P-gp and
showed very strong cellular accumulation in these assays when P-gp was inhibited by tariquidar,
but much less accumulation in the cells when P-gp was not inhibited (Figure 4.8, DNR). If a
compound is not a substrate of P-gp, no significant difference in intracellular accumulation of the
compound with or without tariquidar is expected. Figure 4.8 “29”, shows that compound 29 is
not a transport substrate for P-gp [235] and that no significant difference in cellular accumulation
of 29 was observed with or without addition of tariquidar (TQR). Figure 4.8 also presents the
fold accumulation of each of the experimental 29-variants in these assays normalized to the
amount of compound found in the absence of TQR. This data is numerically presented in Table 5
as the ratio of observed accumulation in the presence of tariquidar divided by the accumulation
observed in the absence of tariquidar for each of the experimental compounds. Ratios that are
significantly greater than 1.0 indicate that a compound is very likely a transport substrate of Pgp.
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None of the Group 1 molecules tested presented intracellular accumulations that were
significantly different in the absence versus presence of TQR, similar to the parental compound
29 (Figure 4.8, 216, 227 and 231), indicating that the variants were not transport substrates of
the pump. This data correlates with the observation that 216 and 227 did not activate basal
ATPase activities by P-gp (data not shown; biochemical experiments were performed by Gang
Chen Department of Biological Sciences, SMU). Compound 231 also showed no significant
cellular accumulations in the presence of TQR (Figure 4.8) and only marginally activated basal
ATPase activity of P-gp (data not shown). Taken together, these results suggest that none of the
Group 1 compounds are good transport substrates for P-gp.
Of the Group 2 compounds, variant 238 showed a very large and significant increase in
intracellular accumulation in the presence of TQR (Figure 4.8, 238). Compounds 255 and 286
showed more modest, but statistically significant increases in intracellular accumulation when Pgp was inhibited in the presence of TQR. Compounds 278 and 280 did not show significantly
different intracellular accumulations in the absence or presence of TQR. Based on the activation
of basal ATPase activities (data not shown) by 238, 255 and 286 and supported by their cellular
accumulation data, these three Group 2 variants of 29 are very likely to be transport substrates of
P-gp. Compound 280, based on its activation of basal ATP hydrolysis, may also be a transport
substrate of P-gp, but is not likely to be a good substrate. Group 2 compound 278 is very unlikely
to be a transport substrate of P-gp, since it neither activates basal ATPase (data not shown) nor
did it show significantly increased cellular accumulation in the presence of tariquidar (Figure
4.8, 278).
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Figure 4.8 - Cellular accumulation of 29 variants in the presence of absence of P-gp inhibitor
tariquidar.
Quantitative LC-MS/MS analysis as in of intracellular accumulation of compounds in the
absence or presence of the potent P-gp inhibitor, tariquidar, in the P-gp overexpressing prostate
cancer cell line, DU145 TXR. P-gp substrate daunorubicin was use as the positive control. For
each compound data is normalized to accumulation of compound in the absence of tariquidar.
Each histogram represents the average ± S.D. (n = 6, two independent experiments); *P < 0.05;
***P < 0.001; ****P < 0.0001; NS – not significant). DNR, daunorubicin; TQR, tariquidar.
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Table 4.3 - The intracellular accumulation of 29 variants.
Quantitative LC-MS/MS analysis results of intracellular accumulation of compounds in the
absence or presence of the potent P-gp inhibitor, tariquidar, in the P-gp overexpressing prostate
cancer cell line, DU145 TXR. P-gp substrate daunorubicin (DNR) was use as the positive
control. Data represents the average ± S.D. (n = 6, two independent experiments);
Compound
29

Average intracellular accumulation
(ng/mL)
29.83 ±13.84

Average intracellular accumulation
in presence of tariquidar (ng/mL)
30.60 ±12.81

216

1924.34 ±308.60

2101.66 ±365.00

227

1396.80 ±436.03

1492.98 ±526.57

231

2147.30 ±293.10

2150.02 ±420.12

238

244.67 ±31.60

454.38 ±125.31

255

264.45 ±67.90

320.60 ±105.64

278

833.72 ±173.42

863.10 ±244.26

280

2423.68 ±1034.07

2892.17 ±631.30

286

234.01 ±27.80

293.23 ±37.41

DNR

1312.70 ±346.36

7224.66 ±1960.72

4.2.6 Effects of Group 1 and Group 2 variants on the paclitaxel sensitivity of drug
sensitive prostate cancer cells, DU145TXR and non-cancerous HFL-1 cells.
While 29-variants showed reversal of paclitaxel resistance in cell viability assays in the Pgp overexpressing DU145TXR [172] cancer cells, similarly the effect on non P-pg
overexpressing cells was evaluated using non P-gp overexpressing prostate cancer line, DU145
[194] and non-cancerous human lung fibroblast cells, HFL-1[173]. The toxicity of the
chemotherapeutic, paclitaxel, was not increased in the presence of 29 or 29-variants in cells that
do not overexpress P-gp (Figure 4.9). These results indicate that increased lethality of paclitaxel
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to the P-gp overexpressing cells was due to the inhibition of the pump and increased
accumulation of paclitaxel to therapeutic levels within the cells.
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Figure 4.9 - Variants from both Groups do not increase the paclitaxel toxicity in cells with
no overexpression of P-gp.
The prostate cancer cell line, DU145 with no overexpression of P-glycoprotein was treated with
either paclitaxel (PTX) or paclitaxel and 10 µM of the P-gp inhibitors Group 1 (panel A) or
Group 2 (panel B). Metabolic activity assays using MTT were performed as described in
Methods.
4.3

Materials and methods

4.3.1 Cell lines and cell culture
The chemotherapeutic sensitive DU145 human prostate cancer cells [194] as well as the
multidrug resistant sub-line, DU145TXR [172] were generous gifts from Dr. Evan Keller
(University of Michigan, Ann Arbor, MI). The multidrug resistant DU145TXR was maintained
under positive selection pressure by supplementing complete medium with 10 nM paclitaxel
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(Acros Organics, NJ). Both cell lines were maintained in complete media consisting of RPMI1640 with L-glutamine, 10% fetal bovine serum (FBS; BioWest, Logan, UT), 100 U/mL
penicillin and 100 μg/mL streptomycin in a humidified incubator at 37°C and 5% CO2. The
noncancerous human fetal lung cell line, HFL1[173] was kindly provided by Dr. Robert Harrod
(Southern Methodist University, Dallas, TX) and maintained in complete media consisting of F12K with L-glutamine, 10% FBS (BioWest, Logan, UT), 100 U/mL penicillin, and 100 μg/mL
streptomycin in a humidified incubator at 37°C and 5% CO2. To promote attachment of HFL1
cells, growth surfaces were treated with 0.1 mg/mL rat tail collagen (BD Biosciences, Palo Alto,
CA) in 0.02 N acetic acid for 10 min and rinsed with PBS prior to use. Cell culture materials
were purchased from Corning Inc. (Corning, NY) unless otherwise stated.
4.3.2 Synthesis of 29 variants
All of the 29 variants were synthesized by Ms. Maha Aljowni in the laboratory of Dr. Alex
Lippert, in the Chemistry Department at SMU (Wise et al. unpublished).
4.3.3 MTT cell viability assay
Cells were trypsinized from monolayers and seeded with 3000 cells in 150 μL of complete
medium in a 96 well plate. After 24 hours, cells were treated for 48 hours with paclitaxel (Acros
Organics, NJ) and / or P-gp inhibitory compounds dissolved in DMSO, or DMSO controls. All
additions were diluted into complete medium. After 48 hours of treatment, MTT assays were
performed as described [193] using 5 mg/mL of MTT (Acros Organics, NJ) solution prepared in
PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4). After 4 hours of
incubation with MTT, the media was removed and the formazan crystals were dissolved in
100 µL of DMSO. The absorbance at 570 nm was then measured using a BioTek Cytation 5
imaging multi-mode reader (Bio-Tek, Winooski, VT). Percent viability was calculated using
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DMSO treated cells as representative for 100% viability. Background absorbance was
determined using MTT and complete medium without cells and subtracted from all the test
values.
% Viability =

Absorbance at 570 nm of test well
Absorbance at 570 nm of DMSO treated cells

The results were plotted as the mean with standard deviation (SD) of eight replicates per
concentration from at least two independent experiments. The graphical representations and IC50
values were determined using four parameter variable slope non-linear regression, using the
following equation: Y=bottom+(top-bottom)/(1+10^((logIC50-X)*Hill Slope) (GraphPad
Prism™, La Jolla California, USA, Version 6.05). The reported “fold sensitization” was
calculated as follows.

Fold sensitization=

IC50 value of A2780ADR cells treated with chemotherapeutic only
IC50 value of A2780ADR or A2780 cells treated with chemotherapeutic
and P-gp inhibitory compound

4.3.4 Calcein AM assay
To assess inhibition of P-gp-catalyzed transport of the P-gp pump substrate, calcein AM,
DU145TXR cells were seeded in 96 wells plates and allowed to grow in complete medium until
reach confluency. Medium was removed, and cells were treated without 2 μM P-gp inhibitory
compounds and 1 μg/mL calcein AM (Life Technologies, OR) and diluted into phenol red free
RPMI 1640 media. To study the effect of pre-incubation of compounds cells were treated with
just P-gp inhibitory compounds and incubated in 37 °C for six hours before adding calcein AM.
Fluorescence excitation at 485 nm with a 20 nm gate and at emission at 535 nm with a 20 nm
gate was measured using a BioTek Cytation 5 imaging multi-mode reader (Bio-Tek, Winooski,

96

VT) over 60 minutes in 20 minute intervals. DMSO was used as vehicle. Results were plotted as
the mean with standard deviation (SD) of six replicates per concentration and are representative
of at least two independent experiments.
4.3.5 Cellular Accumulation Assays for Experimental P-gp Inhibitors
Cells used (DU145TXR), cell culturing, cell exposure to compounds, cellular handling and
extractions were performed as described in [235]. LC-MS/MS methods were performed as
described in [201] and as modified in [235].
4.4

Discussion
Compound 29 is a P-gp inhibitor which is not a P-gp substrate [235]. According to Brewer

et al. there is evidence that inhibitor 29 acts as an allosteric inhibitor of P-glycoprotein [164].
Inhibitor 29 reduces the verapamil stimulated activity of P-gp in proteins assays and it shows the
properties of a P-gp inhibitor in in vitro cellular assays as well [164], [235]. Nevertheless, it does
not affect the ATP binding of P-gp according to electron resonance spectroscopy (ESR)
experiments described in [164]. Based on these observations, it was suggested that P-gp inhibitor
29 may be an allosteric inhibitor and this was a main reason why 29 was selected for further
development. Our focus was to identify P-gp inhibitors which are not P-gp pump substrates as
pump substrates such as verapamil had limited or no success in clinical trials as they were
required in high systemic concentrations leading to toxicity [11].

Here we discuss the in vitro results of eight variants after lead optimization of original
inhibitor 29. These variants were assigned into two different groups based on how they were
derived. The compounds of Group 1 (216, 227 and 231) were generated by ChemGen software,
an in-lab production that can generate variants of a given molecule within the controlled
parameters such as molecular weight. The resulting 29 variants from ChemGen were submitted
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to in silico docking and variants that showed higher affinities to NBDs, and low estimated
affinity for the DBD of P-gp than did the parental 29 were synthesized by our collaborators from
SMU Chemistry (Lippert and Aljowni) (216, 227 and 231). Variants of Group 2 (238, 255, 278,
280 and 286) were synthesized by a conventional “rational design” methods, by visualizing the
binding poses in complex with P-gp and varying shape, size and physicochemical properties of
the original inhibitor 29 following conventional lead optimization methods. All these compounds
were chosen for relative ease of synthesis as well as availability and expense of precursors.

All these variants (both Group 1 and 2) reversed MDR in the P-gp overexpressing prostate
cell line. According to the calculated IC50 values from viability assays, 227 and 231 from Group
1 exhibited nearly 5 and 10 fold improvement respectively in reversing MDR at 10 µM
compared to the parental 29 P-gp inhibitor. This correlated with the predicted improved affinities
of these variants in computational studies performed by John Wise (computational data is not
shown).

In calcein accumulation assays it appeared that Group 2 variants performed better than the
Group 1 variants of 29. We hypothesized that Group 1 compounds were more hydrophobic than
29 which may be delaying the interaction with P-gp by remaining in plasma membrane for a
more extended time. The improved efficacy of Group 1 inhibitors in accumulating calcein after 6
hour incubation with inhibitors than without any incubation provided some support for this
hypothesis. In addition, 238 from Group 2 exhibited nearly 300 fold improvement of MDR
resensitization when compared with parental 29 at 10 µM concentration. However, our strategy
in this project was to identify P-gp inhibitors that are not P-gp transport substrates since P-gp
substrates have failed in clinical trial settings to reverse MDR [11]. When cellular accumulation
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of the inhibitors was assessed in the presence or absence of a strong P-gp inhibitor, tariquidar,
the results suggested that all inhibitors in Group 1 were not transport substrates while four out of
five of the Group 2 inhibitors likely are transported by the pump. The data suggest that all Group
1 compounds and only 278 from Group 2 seemed to reverse the MDR of the cancer cells by
being true enzymological inhibitors of P-gp. P-gp is known to have the ability to transport
molecules with very different shapes and properties [7], [53], [268]. This study shows how only
subtle differences in very similar molecules can be differentiated by P-gp, making some transport
substrates, while others act as real inhibitors of transport by P-gp.

Over all this study produced four more P-gp inhibitors (216, 227, 231 and 278) that
reversed MDR in in vitro. These four inhibitors are variants of the original P-gp inhibitor 29
and showed higher efficacy in reversing MDR in P-gp overexpressing prostate cancer cell
lines compared to inhibitor 29. Further experiments are required to evaluate their
effectiveness in in vivo. Their stability under in vivo conditions is especially important as one
of the inhibitors (227) was found not be stable and was quickly degraded in mouse liver
homogenate (data not shown). Analyzing the degraded products of these compounds
submitted to in vivo conditions will predict the unstable positions of molecules and those
position should be modified to increase the stability and but also retaining P-gp inhibitory
action of the compound.
This study has clearly shown the effectiveness of computational lead optimization in
drug discovery as all three variants from Group 1 reversed MDR without being substrates for
P-gp. A computational based method will be much more advantageous in procedures like
screening for P-gp inhibitors which are non substrates as proteins like P-gp are evolutionarily
adapted to pump various molecules. This approach may reduce the number of compounds
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needed to be tested in the laboratory in in vitro or in vivo conditions saving overall cost and
time in identifying drugs. In future the similar approach we used to lead optimize the P-gp
inhibitor 29 can be used to optimize the other P-gp inhibitors (34 and 45) we have discovered
in previous studies [164], [165], [235].
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5 CHAPTER 5: REVERSAL OF BREAST CANCER RESISTANCE PROTEINMEDIATED MULTIDRUG RESISTANCE WITH NOVEL COMPOUNDS IN
MULTIDRUG RESISTANT BREAST CANCER CELLS
5.1

Introduction
Breast cancer resistance protein (BCRP) is an efflux transporter which belongs to the same

ATP-binding cassette (ABC) protein super family as P-glycoprotein [4], [5], [107], [233]. ABC
family transporters including BCRP can transport xenobiotics out of the cells thus play a major
physiological role in human biological barriers such as blood brain barrier (BBB) [269]–[271]
and the placenta [272]–[274]. Overexpression of BCRP in cell culture models has resulted in
MDR cell lines [191], [275]. BCRP overexpression has also been correlated with poor prognoses
of hematopoietic malignancies and solid tumors, since BCRP can transport a variety of
chemotherapeutic classes such as topoisomerase inhibitors, anthracyclines and tyrosine kinase
inhibitors [107].
Other than its implication in MDR cancers, BCRP plays a key role in preventing drug
penetration through BBB [269], [270], [276]. ABC transporters including BCRP limit the drug
entrance to brain thus, in the case of central nervous system (CNS) diseases, preventing the drug
from reaching the target. Other than some chemotherapeutics which are used for treating brain
tumors [276], several drugs that are used for epilepsy [277] and HIV [278] are also known to be
BCRP substrates. Simultaneous inhibition of BCRP and P-gp has been evaluated for increasing
the efficacy of therapeutics that target the brain tumors [147], [279]. Furthermore, the use of
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BCRP inhibitors has exhibited incremental increases in oral availability of anti-cancer drugs
aswell. However, BCRP inhibitors have shown no clinical successes in the few human trials
concluded so far [159], although several have proven to be successful in in vitro [280] and in
vivo [151] studies.
In this study, we have screened for BCRP inhibitors from a group of small molecules
available in the lab. These molecules were selected and obtained from computational highthroughput screenings of millions of drug-like molecules freely available in online databases
[170], [171] by docking studies using homology models of P-gp and/or BCRP. As BCRP and Pgp both belong to the ABC protein super family and P-gp and BCRP inhibitors are known to
cross-react with other ABC transporters, we predicted that identifying BCRP inhibitors in a pool
of molecules that was originally targeted for P-gp may well be possible. Here we identify and
characterize several BCRP modulators and one BCRP inhibitor that have the capability of
increasing the accumulation of BCRP substrates and of reversing BCRP mediated MDR in a
BCRP overexpressing breast cancer cell line. Furthermore, these inhibitors are shown to increase
the intracellular accumulation common substrates of BCRP and P-gp in a human blood brain
barrier cell line demonstrating the potentiality of the inhibitors to open the BBB.
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5.2

Results

5.2.1 Continuous growth of drug-sensitive MCF-7 cells in mitoxantrone resulted in a
BCRP-overexpressing and mitoxantrone-resistant derivative cell line
A mitoxantrone-resistant, BCRP over-expressing breast cancer cell line (MCF-7 M100) was
established from a mitoxantrone-sensitive parental cell line (MCF-7) [190] by passaging on
media containing increasing concentrations of mitoxantrone essentially as previously described
[191][275] (see Methods for details). Initially, the drug sensitive MCF-7 breast cancer cells were
cultured in media containing 2 nM of mitoxantrone. Gradually the concentration of mitoxantrone
was increased in between passages. After 60 passages, the resultant cells remained viable in up
to 100 nM of mitoxantrone in the medium. The tolerability of mitoxantrone by these breast
cancer cells was qualitatively evaluated by observing the morphological characteristics and cell
doubling time. The overexpression of the BCRP protein in these cells was confirmed by Western
blot analysis (Figure 5.1, Panel A). According to the Western blot analysis, parental MCF-7 did
not express detectable amounts of BCRP, while an intense band corresponding to the size of
BCRP (72 Kda) was observed in MCF-7 M100 cell lysate.
These MCF-7 M100 cells also showed reduced viability when they were treated with
mitoxantrone in the presence of Ko143, a known inhibitor of BCRP [151], as compared to
mitoxantrone treatment alone (Figure 5.6, right most histogram). Further, these cells exhibited a
higher intracellular accumulation of the BCRP substrate, Hoechst 33342 [88], [281], after
treating with Ko143. The P-gp modulator, verapamil [282], in similar experiments did not show
any effects on the intracellular accumulation of Hoechst 33342 in these cells (Figure 5.1, Panel
B). These results strongly suggest that over-expression of BCRP was responsible for the
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mitoxantrone resistance observed in the MCF-7 M100 cell line and that over-expression of P-gp
did not play a role in their MDR phenotype.

Figure 5.1- MCF-7 M100 cells are mitoxantrone resistant due to overexpression of BCRP
A - Western blot analysis of protein expression in cell lysates from breast cancer cell lines MCF7 (drug sensitive) and MCF-7 M100 (multidrug resistant) performed as described in methods.
Top: Western blot analysis of MCF-7 and MCF-7 M100 was performed using anti BCRP
antibody B1 (from Santa Cruz Biotechnology, CA). Bottom: The lower half of the same gel was
probed with β-actin monoclonal antibody C4 (from Santa Cruz Biotechnology, CA). Lane 1
(from left)- Spectra™ Multicolor Broad Range Protein Ladder (catalog # 26623), Visible bands
from top to bottom in the two panels represent 260, 140, 100, 70, 50, 40, 35 kDa, respectively.
Lane 2 - total cell extract from cell line MCF-7 (drug sensitive breast cancer cell line), 5 µg.
Lane 3 - total cell extract from cell line MCF-7 M100 (multidrug resistant breast cancer cell
line), 5 µg.
B – Qualitative and quantitative BCRP transport activity in MCF-7 M100 cells were analyzed
using the BCRP substrate, Hoechst 33342, as described in Methods. Approximately 9 fold
increase in intracellular Hoechst accumulation (Panel B, right) was observed in MCF-7 M100
cells treated with 1 µM of BCRP inhibitor Ko143 resulting a higher fluorescence (Panel B, left)
compared to vehicle (DMSO) treated cells as imaged with a DAPI channel. P-gp modulator
verapamil (VER, 10 µM) had no influence in these cells. Each histogram presents the average ±
S.D. of the determinations (n>8, Replicates from two individual experiments; **** P < 0.0001;
NS - not significant).
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5.2.2 Compounds 50, 53, 70, 71, 83, 103, and 117 induced higher intracellular
accumulation of the BCRP substrate, Hoechst 33342, in BCRP overexpressing
MCF-7 M100 breast cancer cells
An assay utilizing the fluorescent dye, Hoechst 33342 (see Methods), which is a good
transport substrate of BCRP, was used here to potentially identify small drug-like compounds
that inhibit BCRP function. Hoechst 33342 is a cell membrane permeable, nuclear stain that
becomes fluorescent upon binding to DNA [283], [284]. The dye can be efficiently effluxed by
BCRP as a substrate [285], [286]. Inhibitors of BCRP can interfere with the BCRP-catalyzed
efflux of Hoechst 33342 which results in a higher intracellular accumulation of the dye relative
to controls without BCRP inhibitors. Differences in fluorescence intensities can then be
quantitatively measured and compared to give indications of BCRP-specific inhibition [281].
A collection of small drug-like compounds available in the laboratory (numbered from 11
to 124 including several variants of compound 29 described above) were screened here to
identify whether any of these compounds might inhibit BCRP. Each member of the compound
library was acquired or synthesized for testing as a potential ABC transporter inhibitor in related
studies on P-glycoprotein. Each of these compounds was assayed for intracellular Hoechst 33342
accumulation in the BCRP-overexpressing cell line MCF7 M100 to recognize possible BCRP
inhibitors. The results of these assays are presented in Figure 5.2, Figure 5.3 and Figure 5.4.
Compounds 50, 53, 70, 71, 83, 103, and 117 (shown in the contrasting gray histograms in Figure
5.2, Figure 5.3 and Figure 5.4) exhibited the highest BCRP modulation activities resulting in an
approximately 4-fold fluorescence intensity increase compared to vehicle treated cells. These
eight compounds were selected to further analyze their ability reverse the chemotherapeutic
resistance in BCRP overexpressing cells.
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Figure 5.2 - Hoechst 33342 accumulation by compounds 11-48 in MCF-7 M100 cells
Fold accumulation of Hoechst 33342 in MCF-7 M100 cells treated with compounds 11 – 48.
Data are represented as mean ± s.d., n>6.
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Figure 5.3 - Hoechst 33342 accumulation by compounds 49-86 in MCF-7 M100 cells
Fold accumulation of Hoechst 33342 in MCF-7 M100 cells treated with compounds 49-86.
Selected BCRP modulators for further studies are indicated in grey bars. Data are represented as
mean ± s.d., n>6
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Figure 5.4 - Hoechst 33342 accumulation by compounds 87-124 in MCF-7 M100 cells
Fold accumulation of Hoechst 33342 in MCF-7 M100 cells treated with compounds 87-124.
Selected BCRP modulators for further studies are indicated in grey bars. Data are represented as
mean ± s.d., n>6.
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Interestingly, several variants of compound 29, compounds 231, 238, 255 and 286, which
are currently in optimization studies for P-gp inhibition, exhibited the highest BCRP modulation
activities of approximately 4-fold fluorescence increases compared to vehicle treated cells
(Figure 5.5). Variants 231, 238 and 255 were selected to further analyze their ability reverse the
multidrug resistance in BCRP overexpressing cells. Compound 286 exhibited a higher toxicity in
a previous study and was therefore not included in the BCRP studies.
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Figure 5.5 - Hoechst 33342 accumulation by 29 derivatives in MCF-7 M100 cells
Fold accumulation of Hoechst 33342 in MCF-7 M100 cells treated with 29 derivatives. Selected
BCRP modulators for further studies are indicated in grey bars. Data are represented as mean ±
s.d., n = 12.

109

5.2.3 Compounds 50, 71 and 117 reversed the mitoxantrone resistance and showed the
least toxicity to the BCRP overexpressing breast cancer cells
Compounds 50, 53, 70, 71, 83, 103, and 117 which were the most promising candidates for
BCRP-inhibitors identified in the Hoechst 33342 screening were analyzed for their ability to
reverse drug resistance in the MCF-7 M100 cells by interfering with BCRP activity. In these
experiments, cells were treated with 10 µM of compounds 50, 53, 70, 71, 83, 103, and 117
individually with or without 200 nM of mitoxantrone and observed with MTT viability assays
(Methods) to study both the toxicity of the compounds towards cancer cells and to evaluate their
potential to reverse mitoxantrone resistance. Compounds 53, 70, 83 and 103 reduced the viability
of cancer cells significantly by themselves (no added chemotherapeutic) (Figure 5.6), indicating
relatively high toxicity towards the MCF-7 M100 cells. In contrast, compounds 50, 71 and 117
did not show substantial cytotoxicity. Most importantly their combined treatment with
mitoxantrone resulted a decreased viability in cells increasing the mitoxantrone toxicity (Figure
5.6). Compounds 50, 71 and 117 therefore assumed to be potential BCRP inhibitors which
reverse the BCRP mediated MDR. These three compounds need to be studied further in different
BCRP overexpressing cell lines and also need to be confirmed as non BCRP substrates.
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Figure 5.6 - Reversal of mitoxantrone resistance by predicted BCRP inhibitors
MCF-7 M100 cells were treated with 200 nM of the chemotherapeutic mitoxantrone (MNT) and
either compound 50, 53, 70, 71, 83, 103, or 117 at 10 µM, Ko143 at 1 µM, as indicated in the
figure. After 72 hours viability was measured using MTT assay as described in methods. Each
histogram presents the average ± S.D. of the determinations (n=8, Replicates from two individual
experiments)
5.2.4 29 variants 231, 238 and 255 reversed the MDR phenotype in BCRP overexpressing
breast cancer cells
The Hoechst accumulation assay results reported in Figure 5.5 identified three
derivatives of 29 that appeared to be good candidates as BCRP inhibitors. These compounds,
231, 238 or 255, were tested in MTT viability assays (Methods) for the ability to reverse
multidrug resistances in the MCF-7 M100 cell line. Various concentrations of three different
chemotherapeutics (mitoxantrone, topotecan and SN-38), all of which are BCRP substrates, were
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tested individually with 10 µM of 231, 238 or 255 to quantitate their ability to reverse MDR in
the BCRP-overexpressing cell line. We observed that all three putative inhibitors reversed the
chemotherapeutic resistance to very similar levels in the BCRP overexpressing MCF-7 M100
cells (Figure 5.7). The highest efficacy of these inhibitors was exhibited against mitoxantrone
(Figure 5.7, Panel A) compared to topotecan and SN-38. It should be noted that these cells have
shown 100% viability with complete resistance towards ~100 nM of all three of the
chemotherapeutics (without inhibitors) used in these viability assays (Figure 5.7). We observed
that the viabilities dropped to about 50% when the chemotherapeutics (at 100 nM concentration)
were combined with the potential BCRP inhibitors at 10 µM. These cells remained viable (~
50% viability) even at very high concentrations of chemotherapeutics such as 10 µM. But when
combined with potential inhibitors, the viability has reduced to almost 0% completely reversing
the resistance. Further, in experiments using the MCF-7 drug-sensitive parental cell line, the
three putative BCRP inhibitors, 231, 238 and 255 had no effect in viability assays analogous to
those performed with MCF-7 M100 cells (Figure 5.7, Panel D). These results strongly suggest
that the reversal of the MDR phenotype by compounds 231, 238 and 255 was due to their
interaction with BCRP.
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Figure 5.7 - Compounds 231, 238 and 255 reverse the MDR in BCRP overexpressing breast
cancer cells
MCF-7 M100 (Panel A, B and C) cells were treated in the presence of compounds 231, 238, 255
at 10 µM or Ko143 at 1 µM with the indicated concentrations of chemotherapeutics. A –
Mitoxantrone (MNT), B – Topotecan (TOP), C – SN-38. D - MCF-7 cells were treated in the
presence of compounds 231, 238, 255 at 10 µM concentration or Ko143 at 1 µM with the
mitoxantrone. Viability was determined by MTT assay after 72 hours. Experiments were
duplicated and representative figures are shown. Data represents the mean ± SD and n=4.
5.2.5 Compound 231, 238 and 255 resulted higher intracellular accumulation of BCRP
substrates in BCRP overexpressing breast cancer cells
To understand the kinetic properties of BCRP modulation by compounds 231, 238 and 255,
the Hoechst 33342 assay (Methods) was utilized with or without a pre-incubation step with the
putative inhibitors. The results presented in Figure 5.8, Panel A suggested that the effects of
compound 238 and 255 in interfering with BCRP transporter activity as demonstrated by the
increasing Hoechst 33342 intracellular fluorescence occurred at a rate that was about twice that
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of observed for compound 231(Figure 5.8, Panel A). Since all three inhibitors showed
indistinguishable effects in the viability assays (Figure 5.7) that were performed over 72 hours,
we hypothesized that the differences between the inhibitors may be due to their abilities to
penetrate the cell membrane and to interact with BCRP. To test this hypothesis, we incubated the
BCRP overexpressing MCF-7 M100 cells with potential inhibitors for 3 hours prior to addition
of the Hoechst dye. After the 3 hour preincubation step, all three inhibitors produced
significantly higher accumulations of Hoechst 33342 compared to vehicle controls, and the level
of fluorescence intensity reached for each inhibitor was indistinguishable (Figure 5.8, Panel B)
supporting the hypothesis. In additional experiments, we observed that the putative inhibition of
BCRP for each of the compounds was concentration dependent, resulting in considerable
amounts of Hoechst accumulation even at the low concentration of 2.5 µM of each putative
inhibitor (Figure 5.8, Panel C).
In additional experiments, we correlated the reversal of MDR in MCF-7 M100 cells in
viability assays (Figure 5.7) with higher intracellular accumulation of chemotherapeutics in the
presence of the inhibitors compounds. Treatment with 231, 238 and 255 increased the
intracellular accumulation of mitoxantrone and daunorubicin marginally, but statistically
significantly (Figure 5.8, Panel E and Figure 5.9). It is therefore seemed likely that the observed
reversal of MDR in BCRP overexpressing cancer cells in these experiments was due to increased
chemotherapeutic accumulation in the presence of the putative BCRP inhibitors.
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Figure 5.8 - Compounds 231, 238 and 255 increased the accumulation of BCRP substrates
in BCRP overexpressing breast cancer cells
MCF-7 M100 cells were treated with Hoechst 33342 and without (Panel A) or after (Panel B) a
3-hr preincubation with 10 µM of the indicated predicted BCRP inhibitors. The effect of
concentration of inhibitors was evaluated using a Hoechst assay (Panel B) and by measuring
fluorescence (Panel C) and imaging with a DAPI channel (Panel D). Intracellular accumulation
of chemotherapeutics, mitoxantrone (Panel E) and daunorubicin (Panel F) was measured after
treating cells with compounds at 25 µM concentration and lysing the cells as described in
Methods. Fold accumulation was calculated compared to vehicle (DMSO) treated wells.
Experiments were at least duplicated, and representative figures are shown. Data are represented
as mean ± s.d., n>6.
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5.2.6 Compounds 231, 238 and 255 resulted in higher intracellular accumulation of
BCRP and P-gp common transport substrates in immortalized human cerebral
microvascular endothelial cells
The human cerebral microvascular endothelial cell line, hCMEC/D3 [287], an in vitro
blood brain barrier model [288]–[290], was used to analyze the accumulation of transport
substrates that are common to both BCRP and P-gp upon simultaneous inhibition of both
transporters by compounds 231, 238 or 255. As described earlier, we showed that 231 is a P-gp
inhibitor and 238 or 255 are P-gp substrates which reversed P-gp mediated MDR. Hence, we
predicted that inhibition of both P-gp and BCRP would lead to a higher accumulation of P-gp
and BCRP common substrates in the BCRP and P-gp expressing hCMEC/D3 cell line [291].
These results would demonstrate the potential of these new inhibitor compounds to open blood
brain barrier for increasing drug penetration to the brain. In these experiments, we used Hoechst
33342 [292] and rhodamine 123 [287] which are both known to be transport substrates of BCRP
and P-glycoprotein. After treating the hCMEC/D3 cells as described in Methods, we observed
a significantly higher accumulation of rhodamine 123 in a concentration dependent manner
compared to vehicle treated cells (Figure 5.9, Panel A). Compounds 238 and 255 exhibited a
higher efficacy in facilitating accumulation of rhodamine compared to 231. We also note that
treatment of these cells with compounds 231, 238 and 255 each marginally, but statically
significantly increased the intracellular accumulation Hoechst 33342 (Figure 5.9, Panel B).
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Figure 5.9 - Compounds 231, 238 and 255 increased the accumulation of P-gp and
BCRP common substrates in human cerebral microvascular endothelial cells
Blood brain barrier model cell line – hCMEC/D3 cells were treated with compounds 231, 238 or
255 for 3 hours and were exposed to either rhodamine 123 (R123) or Hoechst 33342 as described
in Methods. Fluorescence was measured as described in Methods and fold accumulation
compared to vehicle (DMSO) were calculated and graphed for rhodamine 123 (Panel A) and
Hoechst 33342 (Panel B). Data are represented as mean ± s.d., n=6. (** P < 0.01; *** P < 0.001;
**** P < 0.0001; NS - not significant.)
5.2.7 Compound 231 is not a BCRP substrate while compounds 238 and 255 are BCRP
substrates.
Cell accumulation assays for 231, 238 and 255 variants were performed as in [235] (see
Methods) to more directly assess whether the compounds were transport substrates for BCRP.
These assays measured the intracellular accumulation of the experimental compounds using LCMS/MS methods after incubation with the BCRP overexpressing cell line, MCF-7 M100, in the
absence and presence of the strong BCRP inhibitor, Ko143 [151]. Low levels of cellular
accumulation of a compound in the absence of Ko143 accompanied by much higher levels of
accumulation in the presence of Ko143 strongly suggests that the compound in question may be
a transport substrate of BCRP. Mitoxantrone is an example of a good transport substrate for
BCRP and showed very strong cellular accumulation in these assays when BCRP was inhibited
by Ko143, but much less accumulation in the cells when BCRP was not inhibited (Figure 5.10,
Panel B). If a compound is not a substrate of BCRP, no significant difference in intracellular
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accumulation of the compound with or without Ko143 would be expected. The results of the
accumulation experiments (Figure 5.10, Panel A) strongly suggest that compound 231 does not
function as a transport substrate for BCRP, i.e. no significant difference in cellular accumulation
of compound 231 was observed with or without addition of Ko143. We can state with some
assurance that 231 interfered with the transporter activity of BCRP in viability and BCRP
substrate accumulation assays by inhibiting BCRP function and not by acting as a BCRP
transport substrate. In contrast, compounds 238 and 255 displayed significant increases in their
cellular accumulation upon BCRP inhibition by Ko143 (Figure 5.10, Panel B and C) indicating
they are transport substrates of BCRP. It is likely that these two compounds interfered with
BCRP transporter activity of other substrates like the Hoechst dye (Figure 5.5) by being a
competitor for transport at the drug binding domain of BCRP.
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Figure 5.10 - Compounds 231 is not a transporter substrate for BCRP while compounds 238
and 255 are transport substrates.
Quantitative LC-MS/MS analysis of intracellular accumulation of 231 (panel A), 238 (panel B),
255 (panel C), or mitoxantrone, MNT (panel D) in MCF-7 M100 with or without BCRP inhibitor
Ko143 as described in Methods. Each histogram represents the average ± S.D. (n=6 from two
independent experiments); **** P < 0.0001; NS - not significant).
5.3

Materials and methods

5.3.1 Cell lines and cell culture
A drug sensitive MCF-7 breast cancer cell line (obtained from ATCC) [190] and the
mitoxantrone resistant derivative of MCF-7 (MCF-7 M100) were maintained in complete
media consisting of RPMI-1640 with L-glutamine, 10% fetal bovine serum (FBS; Corning,
NY), 100 U/mL penicillin and 100 μg/mL streptomycin in a humidified incubator at 37 °C and
5% CO2. The mitoxantrone-resistant line MCF-7 M100 was maintained under positive
selection pressure by supplementing complete medium with 100 nM mitoxantrone (Santa
Cruz Biotechnology, CA). Immortalized human cerebral microvascular endothelial cell line hCMEC/D3 [287] was a generous gift from Dr. Ashlee Moses (Oregon Health and Science
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University, Oregon, USA). These cells were maintained in EBM-2 medium (Lonza, MD)
supplemented with EGM-2 MV medium (Lonza, MD), 1% Chemically defined lipid
concentrate (Gibso, USA), 5% fetal FBS (Corning, NY), 100 U/mL penicillin and 100 μg/mL
streptomycin in a humidified incubator at 37 °C and 5% CO 2. To promote attachment of
hCMEC/D3 cells, growth surfaces were treated with 0.1 mg/mL rat tail collagen (BD
Biosciences, Palo Alto, CA) in 0.02 N acetic acid for 10 min and rinsed with PBS prior to use.
Other cell culture materials were purchased from Corning Inc. (Corning, NY) unless
otherwise stated.
5.3.2 Establishment of a multidrug resistant BCRP overexpressing breast cancer cell line
A BCRP over-expressing breast cancer cell line, MCF-7 M100, was established by us
according to previously described methods [191][275]. Briefly, the initially drug sensitive
MCF-7 [190] breast cancer cells were exposed to 2 nM of mitoxantrone and the concentration
of mitoxantrone was increased gradually in approximately 2-fold increments between 6 – 10
passages according to their tolerance to the chemotherapeutic. After 60 passages, the resultant
cells could remain viable and grow up to 100 nM of mitoxantrone in their medium.
Thereafter, the MCF-7 M100 cell line was always maintained in medium containing 100 nM
of mitoxantrone.
5.3.3 Western blot analyses
Whole cell lysates were prepared using approximately five million cells from each cell
line. Cells were lysed with 500 μL of SDS buffer (125 mM Tris HCl pH 6.8, 20% v/v
glycerol, 4% w/v SDS and 2% v/v β-mercaptoethanol) containing 5 μL of protease inhibitor
cocktail (P8340, Sigma). The lysates were filtered through a spin column (QIAprep ®) by
centrifugation at 5000 rpm for 5 minutes and used for Western blot analysis. The lysate
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proteins were resolved by denaturing SDS-PAGE [196] for 100 minutes at 110 V and
subsequently transferred to a PVDF membrane (Bio-Rad, CA) using a Mini Transblot cell
(Bio-Rad) for 70 minutes at 110 V. The transfer buffer contained 192 mM glycine, 25 mM
Tris, and 10% methanol. The membrane was blocked overnight at 4 °C with 4% powdered
skimmed milk in TBS-T (12 mM Tris–HCl pH 7.5, 0.5 M NaCl, 0.05% Tween 20). Washed
membranes were incubated with the BCRP-specific monoclonal antibody B1 (obtained from
Santa Cruz Biotechnology, CA), or the β-actin monoclonal antibody C4 (Santa Cruz
Biotechnology, CA), diluted to between 1:500 and 1:2000 in TBS-T and 4% powdered
skimmed milk. Incubation with the primary antibody solution was performed for 2 hours at
room temperature. Washed membranes were subsequently incubated for 1 hour at room
temperature with alkaline horseradish peroxidase-conjugated goat anti-mouse secondary
antibody sc-2005 (Santa Cruz Biotechnology, CA) diluted to 1:10000 in TBS-T containing
4% milk powder. Membranes were washed in TBS-T, and BCRP or β-actin bands were
visualized using an enhanced chemiluminescence detection kit (ECL kit, Thermo Scientific,
IL). Images were recorded using a ChemiDoc TM Touch imaging system (Bio-rad, CA).
5.3.4 Screening for BCRP inhibitors from our in house small molecule library
A collection of small molecules (numbered from 11 to 124 and variants of 29) which were
used for several previous studies were rescreened here to identify potential BCRP inhibitors.
These compounds were either purchased or synthesized in collaboration with Dr. Alex Lippert
and Maha Aljowani from the Chemistry Department at SMU.
The ability of BCRP to efflux the nuclear stain Hoechst 33342 was used as an assay to
identify any small molecules which interfere with BCRP transporter activity [88], [281]. In these
experiments, about 14,000 MCF-7 M100 breast cancer cells were seeded in each well in 96 well
121

plates and allowed to grow until nearly 90 % confluency was reached (4-5 days). At this point,
the media was replaced with phenol red free RPMI media and cells were treated with or without
10 μM of small molecules (11-124 and SMU29 variants 216, 227, 231, 238, 255, 278, 280 and
286) in the presence of 5 μg/mL of Hoechst 33342. Fluorescence was measured with excitation
at 361/20 nm and at emission 497/20 nm using the BioTek Cytation 5 imaging multi-mode
reader (Bio-Tek, Winooski, VT) after 90 minutes of treatment at 37 0C. DMSO (0.5% v/v) was
used as the vehicle control, and 1 μM of the known BCRP inhibitor, Ko143, was used as a
positive control [151] and10 μM of P-gp substrate, verapamil, was used as negative control
[282]. Any compounds that resulted in more than approximately 4-fold increased Hoechst 33342
accumulation compared to the vehicle controls were selected for further studies.
5.3.5 Evaluation of cytotoxicity and reversal of mitoxantrone resistance by compounds
50, 53, 70, 71, 83, 103, and 117
Cytotoxicity and the ability to reverse the mitoxantrone resistance displayed by MCF-7
M100 cancer cells by compounds 50, 53, 70, 71, 83, 103, and 117 were evaluated using MTT
viability assays. About 5000 MCF-7 M100 cells were seeded in each well of 96 well plates for
24 hours and cells were treated with 10 µM compound with or without 200 nM of mitoxantrone
for 72 hours before addition of MTT. The MTT assays were performed as described in [193]
using 5 mg/mL of MTT (Acros Organics, NJ) solution prepared in PBS (137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4). After 4 hours of incubation with MTT, the
media was removed and the formazan crystals that had formed were dissolved in 100 µL of
DMSO. The absorbance at 570 nm was then measured using a Cytation 5 instrument. Percent
viability was calculated using DMSO treated cells as representative for 100% viability.
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Background absorbance was determined using MTT and complete medium without cells.
Background absorbance was subtracted from all of the test values.
5.3.6 Reversal of Multidrug resistance by compounds 50, 71, 117 and 29 variants 231, 238
and 255.
Three of the compounds that performed well in the MTT viability assays, 50, 71, and 117,
were tested again at differing concentrations of mitoxantrone. These assays were performed as
above with mitoxantrone at concentrations of 1 mM, 100 μM, 10 μM, 1 μM, 100 nM, 10 nM, 1
nM, and 100 pM with or without 10 μM of compounds 50, 71, and 117.
The 29 variants (231, 238 and 255) which led to high levels of accumulation of Hoechst 33342 in
MCF-7 M100 cells were tested in viability assay with 10 µM concentrations of 29 variants
similar to the viability assay procedure described above. To assess the reversal of MDR, viability
assays were repeated with two more chemotherapeutics, topotecan and SN-38, as well. Further
impact of these putative inhibitors on parental drug sensitive MCF-7 cells were assayed using the
same assay conditions as described above. The graphical representations were determined
using four parameter variable slope non-linear regression, using the following equation:
Y=bottom + (top-bottom)/(1 + 10^((logIC50-X)*Hill Slope (GraphPad Prism™, La Jolla
California, USA, Version 6.05).
5.3.7 Evaluation of the accumulation of BCRP substrates in BCRP overexpressing MCF7 M100 cells by 29 variants
The concentration dependence and time courses of 29 variants (231, 238 and 255) on
BCRP inhibitory action were studied using the Hoechst assay as described earlier with the
following modifications. Cells were treated with various concentrations (1, 2.5, 5 and 10 µM) of
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putative BCRP inhibitors and 5 μg/mL of Hoechst 33342. Immediately after addition, the
fluorescence was measured with excitation at 361/20 nm and at emission 497/20 nm using the
Cytation 5 every 10 minutes for 50 minutes while maintaining 37 0C.
To study the influence of the preincubation of inhibitors with the cells, another experiment
was performed similar to those described above, but included incubation of the putative
inhibitors for 3 hours in 37 0C before Hoechst 33342 addition. After Hoechst addition,
fluorescence was measured every 10 minutes for 50 minutes while maintaining 37 0C. Imaging
of samples was performed after 50 minutes incubation with Hoechst using a DAPI channel of the
Cytation 5 to observe the qualitative accumulation of Hoechst in MCF-7 M100 cells.
To measure the cellular accumulation of chemotherapeutics, daunorubicin and mitoxantrone
were used. MCF-7 M100 cells were seeded in 96 wells plates at 14,000 cells per well in
complete media and allowed to grow until 100% confluency. Medium was removed and cells
were treated with or without 25 μM potential BCRP inhibitory compounds in the presence of
15 μM daunorubicin (MP Biomedicals, France) or 25 μM mitoxantrone (Santa Cruz
Biotechnology, CA) in complete medium. Vehicle controls were treated with 0.5% DMSO.
After 3 hours of incubation, media were removed and cells were washed three times with 200 µL
of ice cold PBS. The cells were lysed by addition of 100 μL of PBS containing 0.8% SDS and
0.8% Triton X100 immediately after the washing step. The fluorescence of daunorubicin was
measured using excitation at 488 nm (20 nm gate) and emission at 575 nm (20 nm gate). The
fluorescence of mitoxantrone was measured using excitation at 640 nm (10 nm gate) and
emission at 690 nm (10 nm gate) using the also using the Cytation 5 instrument. Fold
accumulation for each of the experiments were calculated compared to vehicle treated cells.
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5.3.8 Evaluation of BCRP and P-gp substrate accumulation in the blood brain barrier
endothelial cell line hCMEM/d3
The immortalized human cerebral microvascular endothelial cell line, hCMEC/D3, were
seeded in 96 well plates with 5000 cells per well and allowed to grow 4 to 5 days until cells
become nearly 100% confluent. Cells were treated with 25 µM of 231, 238 or 255
individually. After 3 hours of incubation, cells were treated with 2.5 µM of rhodamine 123
diluted in media and allowed the cells to accumulate rhodamine 123 for 90 minutes. Then
media were removed and cells were washed three times with 200 µL of PBS. Cells were lysed in
100 μL of PBS containing 0.8% SDS and 0.8% Triton X100 immediately after the washing step.
The P-gp substrate, verapamil (25 µM), was used as a positive control and vehicle controls
were treated with 0.5% DMSO. The fluorescence of rhodamine 123 was measured using
excitation at 488 nm with a 20 nm gate and emission at 575 nm with a 20 nm gate using the
Cytation 5. Fold accumulations were calculated and normalized to vehicle treated cells.
To analyze the Hoechst 33342 accumulation, cells were seeded as above and after reaching
100% confluence, the media was replaced with phenol red free RPMI media. Cells were then
treated with 25 µM of 231, 238, or 255 individually diluted in phenol red free RPMI media and
incubated at 37 oC for 3 hours. After the initial incubation, cells were then treated with 1 µg/mL
of Hoechst 33342. Fluorescence was measured with excitation at 361/20 nm and at emission
497/20 nm using the Cytation 5 after a 50 minute 37 oC incubation with the Hoechst dye. Fold
accumulations were calculated, and normalized vehicle treated cells.
5.3.9 Cellular accumulation assays for experimental BCRP inhibitors
MCF-7 M100 cells were seeded in 6 well plates with ~200,000 cells per well. After
several days when cells were 100% confluent, the media was replaced with fresh media and
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cells were treated with 5 μM of compounds (231, 238, or 255 or mitoxantrone) with or
without 500 nM of Ko143 (Sigma). Experiments were performed in triplicate. After 2.5 hours
of incubation with compounds, cells were washed with Hank’s Balanced Salt Solution (HBSS,
Corning Inc. NY), harvested using trypsin, and counted. Each sample was then washed with
2 mL of ice-cold HBSS and diluted in cold HBSS at a final concentration of 1 million
cells/mL. All samples were frozen with liquid nitrogen and stored at −80 °C until analysis.
Samples were analyzed at the University of Texas Southwestern Medical Center Preclinical
Pharmacology Laboratory using LC-MS/MS analyses essentially as described in [201] and as
modified in [235].
5.4

Discussion
BCRP overexpression is correlated with MDR in cancer and its expression in blood brain

barrier (BBB) plays a major functional role by excluding therapeutics away from brain [107].
BCRP inhibitors have been demonstrated to reverse MDR in cell cultures [280] and their use in
in vivo experiments is correlated with elevated BCRP substrate concentrations in the brain [269].
Nevertheless, these inhibitors have not yet shown success in clinical settings; thus the demand
for clinically approved BCRP inhibitors remains [159]. Computational screenings have been
deployed to recognize drugs successfully over the decades and have been used in attempts to
identify BCRP inhibitors as well [293], [294]. After studying a small library of compounds
selected using a computational based screening, we have identified several BCRP modulating
compounds including one confirmed BCRP inhibitor and two BCRP substrates in this study.
The toxicity of therapeutics is a major drawback in chemotherapy [295]. Out of the seven
compounds which could interfere with BCRP transport activity (50, 53, 70, 71, 83, 103, and 117)
we selected from screens of a library containing 114 compounds using the Hoechst assays
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(Figure 5.3 and Figure 5.4), four of them (53, 70, 83 and 103) had exhibited significant toxicity
by themselves in ealier viability assays (Figure 5.6). The viability experiments should be
repeated using another BCRP overexpressing cell line to confirm this toxicity is not a cell line
specific effect. Although 29 variant 286 exhibited a significant Hoechst accumulation (Figure
5.5) we did not include 286 in viability assays as this compound has exhibited toxicity by itself
to different cell lines in previous studies (Chapter 4).
Since clinical trials using substrates of P-gp such as verapamil as MDR reversing agent
have failed, we wanted to examine whether the 29 variants which modulated BCRP activity were
BCRP inhibitors or as transport substrates. In previous work by others, BCRP substrates have
been confirmed by using cell lines with directional expression of BCRP on transwell plates [296]
or by using vesicle transport assays [93] with BCRP enriched vesicles. Here we have adopted a
relatively facile method equivalent to that described in [235] by analyzing the intracellular
accumulation of compounds in the presence or the absence of a strong, known BCRP inhibitor
(Ko143) to determine whether a given compound functions as a BCRP substrate. As the positive
control we used mitoxantrone, which is a very good transport substrate of BCRP. As indicated in
Figure 5.10, this method cam be reliably used for identification of BCRP substrates with a
BCRP overexpressing cell line even without a directional expression pattern. We have confirmed
that compound 231 is not a BCRP substrate which is importance since we also demonstrated this
compound to not be a substrate of P-glycoprotein. This indicates that 231 reversed the MDR and
increased the BCRP substrate accumulation in the BCRP overexpressing cell line by functioning
as an inhibitor of BCRP turnover. Similar to what we observed with P-gp in earlier experiments,
compounds 238 and 255 accumulated upon BCRP inhibition indicating that both likely are
transport substrates for BCRP. According to the accumulation results obtained from these
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experiments, compound 238 appeared to be a better substrate than was the positive control,
mitoxantrone (Figure 5.10 Panel B and D). In other work, by colleagues in the lab, the ATPase
activity of isolated protein preparations (Gang Chen, data not shown), compound 238 stimulated
basal ATPase activity to a higher extend than the known P-gp substrate, verapamil, again
suggesting that compound 238 might be an excellent transport substrate for P-gp. If compounds
238 and 255 are stable in in vivo conditions, radiolabeled derivatives of these two compounds
coupled with positron emission tomography (PET) imaging might be useful for simultaneous
analyses of P-gp and BCRP function in vivo similar to that described in [297]–[300].
The pool of compounds we analyzed in this study (11-124 and 29 variants) were originally
selected by docking compound structures available in databases of commercially available, small
molecule drug-like compounds to P-gp [44], [164]or BCRP [unpublished] homology models. We
used a BCRP homology model due to the unavailability of a high-resolution structure of the
NBD of BCRP at the time these screenings were performed. We hypothesized that compounds
that were predicted to be P-gp inhibitors by these computational screenings might also have the
potential to show modulatory/inhibitory action on BCRP. This is mainly due to both of these
transporters belonging to the ABC super family of proteins, their similarities in function and
especially in the structures of the nucleotide binding domains of the two proteins [301]. In
support of this assumption, it should be noted that inhibitors like elacridar inhibit both P-gp and
BCRP [302], evidencing the predictability of having BCRP inhibitors in a pool of molecules
targeted to be P-gp inhibitors. The BCRP modulatory compounds which we have identified in
Hoechst accumulation assays using BCRP-overexpressing breast cancer cells in this study (50,
53, 70, 71, 83, 103, and 117) all exhibited P-gp modulatory activities in previous studies
(McCormick et al. unpublished; data not shown). in addition, the 29 variant 231 is a predicted P-

128

gp inhibitor (Chapter 4) and this study illustrates that 231 also functions as a non-transported
BCRP inhibitor as well. Compounds 238 and 255 were identified as BCRP substrates in this
study; both of these compounds are also P-gp substrates (Chapter 4). We predicted that these
inhibitors would elevate the penetration and accumulation of P-gp and BCRP substrates into the
brain through the BBB, as well as in reversing the BCRP and P-gp mediated MDR in cancers. In
vivo experiments should be performed in future to examine the efficacy of these inhibitors. In
vivo and preclinical data have demonstrated the increased oral bio-availability of
chemotherapeutics by the inhibition of both P-gp and BCRP from elacridar [147]. We believe
dual modulation of P-gp and BCRP by the compounds we describe in this study might have the
potential to enhance the bio-availability of CNS targeted therapeutics as well.
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6
6.1

CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS

Conclusions

6.1.1 Compound 29, 34 and 45 are P-gp inhibitors
Multidrug resistance is correlated with poor outcome of chemotherapy and P-glycoprotein
is one of the main reasons for MDR [303], [304]. P-gp inhibitors have shown success in
reversing MDR in in vitro and in vivo, but only with marginal success in clinical trials. Thus
demand for clinically approved P-gp inhibitors remains [305]. One major aim in our studies was
to find P-gp inhibitors that are not P-gp substrates. Previous studies from our group have
recognized compounds 29, 34 and 45 as potential P-gp inhibitors. Here we show that these
inhibitors can reverse MDR in two different P-gp overexpressing cells lines, A2780ADR ovarian
cancer cells and DU145TXR prostate cancer cells, using multiple chemotherapeutics. The
reversal of MDR is correlated with the higher accumulation of P-gp substrates when cells are
exposed to P-gp inhibitors. P-gp inhibitors 34 and 45 have no impact on BCRP overexpressing
breast cancer cells, indicating that no functionally detectable interactions with BCRP occurred.
Compound 29 conversely also modulated the BCRP activity. We have proposed a relatively
simple and novel assay for recognizing P-gp substrates in in vitro conditions based on the
accumulation of the compound in the presence or absence of a known P-gp inhibitor tariquidar,
when tested with LC-MS/MS approaches. Using this novel assay, we concluded that these three
compounds are not P-gp transporter substrates. Hence combining the results from cellular
accumulations of these compounds with the results of MDR reversing cell culture assays and
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Western blot analyses for P-gp expression, we concluded that compounds 29, 34 and 45 reverse
the MDR by functioning as inhibitors of P-gp.
6.1.2 Extended treatment of P-gp inhibitor 29 significantly increases the efficacy of
chemotherapy
P-gp inhibitors had only a limited success in clinical settings and one reason could the
treatment strategy [5], [11]. Extended treatment of inhibitor 29 after an initial exposure to both
29 and chemotherapeutics led to a higher retention of chemotherapeutics in the P-gp
overexpressing cancer cells in vitro. Intracellular retention of chemotherapeutics by P-gp
inhibitor 29, even in the absence of free chemotherapeutics in the medium, significantly
improved the outcome of the chemotherapeutic treatments in in vitro assays. Extended treatment
had no impact on cancer cells that do not overexpress P-gp nor did it impact non-cancerous cells.
We can therefore predict that this strategy could be used in vivo or potentially clinically in the
future to enhance the outcome of chemotherapy treatments.
6.1.3 Lead optimization of compound 29 has yielded improved P-gp inhibitors.
One of the most important steps of computational based drug screenings is the lead
optimization. This is the process where “potential” drugs become clinically acceptable by
improving the drug-like characteristics [262]. The three variants (216, 227 and 238) generated
from computational based lead optimization of parental P-gp inhibitor 29 are not P-gp substrates
thus we conclude that these variants reversed the paclitaxel resistance by functioning as P-gp
inhibitors. Only 278 out of five variants (238, 255, 278, 280 and 286) exhibited the P-gp
inhibitor like characteristics which were designed through conventional lead optimization.
Although parental P-gp inhibitor 29 modulates the BCRP activity, variants 216, 227, 278 and
280 do not modulate BCRP activity, showing the improved specificity towards P-gp in their
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variant forms. Improved efficacy of reversing paclitaxel resistance compared to parental P-gp
inhibitor 29 and observing that 100% of computationally designed P-gp inhibitors did not
function as P-gp substrates provides evidence and a strong example of the advantages of using
computationally based lead optimization over more conventional methods.
6.1.4 Potential BCRP inhibitors can reverse BCRP mediated MDR
BCRP is another ABC type transporter which confers MDR in cancer and is also important
in extruding xenobiotics away from brain [147], [270]. We have established a BCRP
overexpressing breast cancer cell line, MCF-7 M100, from the parental cell line MCF-7 to use in
cell-based assays of BCRP inhibitors. Our screenings have resulted in the identification of
several BCRP modulators with the potential to be BCRP inhibitors (50, 53, 70, 71, 83, 103, and
117). Further, we have found that three variants of P-gp inhibitor 29, compounds 231, 238 and
255, also reversed BCRP mediated MDR in vitro. Their ability to reverse MDR in BCRP
overexpressing cancer cells is correlated with increased intracellular accumulation of
chemotherapeutics that are BCRP substrates chemotherapeutics. Here we introduce a novel assay
using LC-MS/MS instrumentation for determining whether any given compound acted as a
BCRP substrate in in vitro cell-based experiments. These assays were developed in analogy with
those described earlier for determining whether compounds act as P-gp substrates. The tests in
this case used cells over-expressing BCRP and LC-MS/MS to quatify the accumulation of the
compounds in the presence or absence of a known BCRP inhibitor, Ko143. Results from these
assays strongly suggest that compound 231 is not a BCRP substrate and that compounds 238 and
255 do function as BCRP substrates using this novel assay. These compound screens identified
two new substrates for both P-gp and BCRP (compounds 238 and 255). These novel substrates
could be useful in the future for various purposes such as determining transporter activity in
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normal or cancerous tissues. Further we can predict that dual modulators of P-gp and BCRP may
eventually prove useful in opening the BBB to drugs that target brain or CNS pathologies.
6.2

Future Directions
Our aim here was to identify novel P-gp and BCRP inhibitors that are not substrates for the

relevant transporters. This study has identified several P-gp inhibitors and BCRP inhibitors that
meet this criteria and other compounds that modulate transporter function while acting as
substrates. screening for new inhibitors as well as optimizing the leads that we have already
identified should continue on to find and / or develop inhibitors with higher binding affinities
and better drug-likeness. These novel inhibitors should be able to reverse MDR in P-gp
overexpressing cell lines in viability assays, increase P-gp substrate intracellular accumulation,
should be tested for the specificity for P-gp, be assessed for their potential of being P-gp
substrates. Successful candidates will have to further undergo testing for metabolic stability
similar to [172]. Stable inhibitors can then be directed to in vivo studies [306]. As described, we
have gained significant improvements in P-gp inhibitor 29 in lead optimization studies. The
ChemGen process we have used for inhibitor 29 may be applied for computationally based lead
optimization of other P-gp inhibitors.
Screening for the identification of novel BCRP inhibitors can be performed efficiently in
future using new BCRP structures with a higher resolution as determined by cryo-electron
microscopy [307]. Ideally, one should test the potential BCRP inhibitors in at least two different
BCRP overexpressing cell lines to confirm that the effects are not cell line specific and the
similar process described for P-gp in above can be applied to identify novel BCRP inhibitors that
can lead to clinical trials. The compounds with dual modulatory activity of both P-gp and BCRP
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can be directed for in vivo BBB studies to analyze potentially higher brain targeted accumulation
of therapeutics which are P-gp and BCRP substrates.
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Martínez, “Hoechst 33342 stain and u.v. laser exposure do not induce genotoxic effects in
flow-sorted boar spermatozoa,” Reproduction, vol. 128, no. 5, pp. 615–621, Nov. 2004.
[285] C. W. Scharenberg, M. A. Harkey, and B. Torok-Storb, “The ABCG2 transporter is an
efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human
175

hematopoietic progenitors.,” Blood, vol. 99, no. 2, pp. 507–12, Jan. 2002.
[286] M. Kim, H. Turnquist, J. Jackson, M. Sgagias, Y. Yan, M. Gong, M. Dean, J. G. Sharp,
and K. Cowan, “The multidrug resistance transporter ABCG2 (breast cancer resistance
protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.,”
Clin. Cancer Res., vol. 8, no. 1, pp. 22–8, Jan. 2002.
[287] B. B. Weksler, E. A. Subileau, N. Perrière, P. Charneau, K. Holloway, M. Leveque, H.
Tricoire-Leignel, A. Nicotra, S. Bourdoulous, P. Turowski, D. K. Male, F. Roux, J.
Greenwood, I. A. Romero, and P. O. Couraud, “Blood-brain barrier-specific properties of
a human adult brain endothelial cell line,” FASEB J., vol. 19, no. 13, pp. 1872–1874, Nov.
2005.
[288] C. J. Czupalla, S. Liebner, and K. Devraj, “In vitro models of the blood-brain barrier,”
Methods Mol. Biol., 2014.
[289] H. C. Helms, N. J. Abbott, M. Burek, R. Cecchelli, P. O. Couraud, M. A. Deli, C. Förster,
H. J. Galla, I. A. Romero, E. V. Shusta, M. J. Stebbins, E. Vandenhaute, B. Weksler, and
B. Brodin, “In vitro models of the blood-brain barrier: An overview of commonly used
brain endothelial cell culture models and guidelines for their use,” Journal of Cerebral
Blood Flow and Metabolism. 2015.
[290] B. Weksler, I. A. Romero, and P. O. Couraud, “The hCMEC/D3 cell line as a model of the
human blood brain barrier,” Fluids and Barriers of the CNS. 2013.
[291] S. Dauchy, F. Miller, P.-O. Couraud, R. J. Weaver, B. Weksler, I.-A. Romero, J.-M.
Scherrmann, I. De Waziers, and X. Declèves, “Expression and transcriptional regulation
of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular
176

endothelial cells,” Biochem. Pharmacol., vol. 77, no. 5, pp. 897–909, Mar. 2009.
[292] F. Tang, H. Ouyang, J. Z. Yang, and R. T. Borchardt, “Bidirectional Transport of
Rhodamine 123 and Hoechst 33342, Fluorescence Probes of the Binding Sites on Pglycoprotein, across MDCK-MDR1 Cell Monolayers,” J. Pharm. Sci., 2004.
[293] F. Montanari, A. Cseke, K. Wlcek, and G. F. Ecker, “Virtual Screening of DrugBank
Reveals Two Drugs as New BCRP Inhibitors,” SLAS Discov. Adv. Life Sci. R&D, vol. 22,
no. 1, pp. 86–93, Jan. 2017.
[294] Y. Pan, P. P. Chothe, and P. W. Swaan, “Identification of Novel Breast Cancer Resistance
Protein (BCRP) Inhibitors by Virtual Screening,” Mol. Pharm., vol. 10, no. 4, pp. 1236–
1248, Apr. 2013.
[295] I. H. Plenderleith, “Treating the treatment: toxicity of cancer chemotherapy.,” Can. Fam.
Physician, vol. 36, pp. 1827–30, Oct. 1990.
[296] Y. Imai, S. Asada, S. Tsukahara, E. Ishikawa, T. Tsuruo, and Y. Sugimoto, “Breast
Cancer Resistance Protein Exports Sulfated Estrogens but Not Free Estrogens,” Mol.
Pharmacol., vol. 64, no. 3, pp. 610–618, Sep. 2003.
[297] G. Pottier, S. Marie, S. Goutal, S. Auvity, M.-A. Peyronneau, S. Stute, R. Boisgard, F.
Dollé, I. Buvat, F. Caillé, and N. Tournier, “Imaging the Impact of the P-Glycoprotein
(ABCB1) Function on the Brain Kinetics of Metoclopramide.,” J. Nucl. Med., vol. 57, no.
2, pp. 309–14, Feb. 2016.
[298] W. Löscher and O. Langer, “Imaging of P-glycoprotein function and expression to
elucidate mechanisms of pharmacoresistance in epilepsy.,” Curr. Top. Med. Chem., vol.
10, no. 17, pp. 1785–91, 2010.
177

[299] S. Eyal, F. S. Chung, M. Muzi, J. M. Link, D. A. Mankoff, A. Kaddoumi, F. O’Sullivan,
M. F. Hebert, and J. D. Unadkat, “Simultaneous PET imaging of P-glycoprotein inhibition
in multiple tissues in the pregnant nonhuman primate.,” J. Nucl. Med., vol. 50, no. 5, pp.
798–806, May 2009.
[300] S. Syvänen and J. Eriksson, “Advances in PET imaging of P-glycoprotein function at the
blood-brain barrier.,” ACS Chem. Neurosci., vol. 4, no. 2, pp. 225–37, Feb. 2013.
[301] V. Vasiliou, K. Vasiliou, and D. W. Nebert, “Human ATP-binding cassette (ABC)
transporter family.,” Hum. Genomics, vol. 3, no. 3, pp. 281–90, Apr. 2009.
[302] R. Sane, S. Agarwal, R. K. Mittapalli, and W. F. Elmquist, “Saturable active efflux by pglycoprotein and breast cancer resistance protein at the blood-brain barrier leads to
nonlinear distribution of elacridar to the central nervous system.,” J. Pharmacol. Exp.
Ther., vol. 345, no. 1, pp. 111–24, Apr. 2013.
[303] G. Lehne, “P-glycoprotein as a drug target in the treatment of multidrug resistant cancer.,”
Curr. Drug Targets, vol. 1, no. 1, pp. 85–99, Jul. 2000.
[304] K. Nooter and G. Stoter, “Molecular Mechanisms of Multidrug Resistance in Cancer
Chemotherapy,” Pathol. - Res. Pract., vol. 192, no. 7, pp. 768–780, Jan. 1996.
[305] F. S. Chung, J. S. Santiago, M. Francisco, M. De Jesus, C. V Trinidad, M. Floyd, and E.
See, “Disrupting P-glycoprotein function in clinical settings: what can we learn from the
fundamental aspects of this transporter?,” 2016.
[306] J. P. Hughes, S. Rees, S. B. Kalindjian, and K. L. Philpott, “Principles of early drug
discovery.,” Br. J. Pharmacol., vol. 162, no. 6, pp. 1239–49, Mar. 2011.
[307] N. M. I. Taylor, I. Manolaridis, S. M. Jackson, J. Kowal, H. Stahlberg, and K. P. Locher,
178

“Structure of the human multidrug transporter ABCG2,” Nature, vol. 546, no. 7659, pp.
504–509, May 2017.

179

180

